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I. Angiogenesis	
Angiogenesis	 is	 the	 formation	of	new	blood	vessels	 from	a	pre-existing	vasculature.	 It	occurs	in	both	health	and	disease,	beginning	during	development	and	continuing	through	old	 age	 (1).	 The	 establishment	 of	 a	 primordial	 vascular	 network	 is	 crucial	 during	development,	 as	 it	 permits	 the	 circulation	 of	nutrients	 and	 oxygen	 in	 the	 tissues	 to	sustain	organism	growth	and	viability.	The	first	process	that	gives	rise	to	blood	vessels	is	vasculogenesis	(Fig.	1),	which	is	characterized	by	the	differentiation,	migration,	and	coalescence	of	mesoderm-derived	endothelial	progenitors	also	known	as	angioblasts	(2).	 The	 primitive	 vascular	 plexus	 remodels	 through	 sprouting	 and	 pruning	(angiogenesis)	 to	 form	 a	mature	 circulation	 (3).	 In	 adult	 life,	 the	 formation	 of	 new	capillaries	occurs	physiologically	during	wound	healing,	organ	regeneration	and	the	female	reproductive	cycle	through	a	strict	balance	between	stimulatory	and	inhibitory	signals.	 Dysregulation	 in	 vessel	 growth	 contributes	 to	 the	 pathogenesis	 of	 many	disorders	 including	malignant	 tumors,	 retinopathy	 and	 psoriasis	 as	well	 as	 obesity,	asthma	 and	 infectious	 disease.	 In	 addition,	 insufficient	 vessel	 growth	 or	 regression	triggers	ischemia,	hypertension	and	other	pathological	conditions	(4).		Angiogenesis	 can	 be	 divided	 into	 two	 main	 phases:	 an	 activation	 phase	characterized	 by	 the	 initiation	 of	 the	 “angiogenic	 cascade”	 and	 a	 resolution	 phase	 in	which	 newly-induced	 vessels	 acquire	 proper	 pericyte	 coverage	 that	 promotes	endothelial	cell	survival	and	helps	to	maintain	vessel	stability.	Tissue	signals	involved	in	the	activation	of	the	endothelium	are	mainly	hypoxic,	metabolic	or	mechanical	stimuli.	Angiogenesis	 is	 stimulated	 in	 chronic	 hypoxic	 conditions	 through	 different	 pathways	including	 nitric	 oxide	 or	 hypoxia-inducible	 transcription	 factors,	 or	 during	 repeated	
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exercises	due	to	increases	in	shear	stress	and	mechanical	strain	in	the	muscle	(5).	Both	signals	 lead	to	the	secretion	of	pro-angiogenic	factors,	 i.e.	vascular	endothelial	growth	factor	(VEGF),	fibroblast	growth	factor	(FGF)	and	angiopoietins	to	the	target	vasculature.										
	
1.1 Molecular	regulation	of	angiogenesis	The	activation	of	 the	endothelium	is	a	crucial	step	 in	enabling	endothelial	cells	 to	exit	their	 vessel	 of	 origin	 and	 progress	 along	 the	 stages	 of	 angiogenesis.	 In	 response	 to	angiogenic	 signals,	 the	 vascular	 bed	 is	 destabilized;	 the	 basement	 membrane	 and	extracellular	 matrix	 are	 selectively	 degraded	 to	 allow	 endothelial	 cell	 migration,	proliferation	 and	 the	 formation	 of	 a	 new	 vascular	 structure	 (6).	 Among	 the	 known	angiogenic	 factors,	the	vascular	endothelial	growth	factor	(VEGF)	is	one	of	the	most	important	 and	 specific	 regulators	 of	 angiogenesis.	 VEGF	 gene	 expression	 is	 up-regulated	 by	 many	 stimuli	 including	 hypoxia,	 the	 release	 of	 growth	 factors	 and	cytokines	or	during	hormonal	regulation	such	as	estrogen	release.	In	response	to	low	
Figure	1.	Vascular	development.	 	Endothelial	progenitor	(angioblasts)	derived	from	the	mesoderm	gives	rise	to	a	primitive	vascular	plexus	(vasculogenesis).	The	remodeling	of	the	embryonic	vascular	network	and	the	formation	of	new	blood	vessels	from	the	pre-existing	vasculature	(angiogenesis)	generates	mature	arteries	and	veins	(Adapted	from	Kjain	R.	et	al,	2003).	
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oxygen	concentration,	the	hydroxylation	of	the	transcriptional	factor	HIF-1α	(hypoxia	inducible	 factor)	 is	 attenuated	 and	 its	 degradation	 is	 prevented.	 HIF-1α	 is	 then	heterodimerize	with	HIF-1β	 and	 translocate	 to	 the	 nucleus	 to	 bind	 hypoxia	 response	element	(HRE)	in	order	to	transactivate	target	genes	such	as	VEGF	(7).	The	interaction	between	VEGF	ligands	and	receptors	is	essential	for	starting	the	angiogenic	process.			
1.1.1 Vascular	Endothelial	Growth	Factors		The	VEGF	family	comprises	seven	subgroups	of	proteins:	VEGF-A,	VEGF-B,	VEGF-C,	VEGF-D,	 VEGF-E,	 VEGF-F	 and	 placenta	 growth	 factor	 (PIGF).	 This	 family	 of	 secreted	polypeptides	 has	 a	 common	 VEGF	 homology	 domain	 composed	 of	 eight	 conserved	cysteine	residues	 involved	 in	 intra-	and	 intermolecular	disulfide	bounds	(cystine	knot	structures)	(8).	VEGFs	are	biologically	active	as	dimers,	primarily	as	homodimers	and	sometimes	as	heterodimers	(9).		VEGF-A	 is	 a	 dimeric	 glycoprotein	 of	 34	 to	 42	 kDa	 involved	 in	 vasculogenesis,	angiogenesis	 and	 in	 the	 differentiation	 of	 hemangioblasts	 to	 hematopoietic	 precursor	cells	during	embryogenesis	(10).	In	physiological	conditions,	the	highest	levels	of	VEGF-A	mRNA	were	 found	 in	adult	 lungs,	kidneys,	hearts	and	adrenaline	glands	and	 less	 in	livers,	 spleens	 and	 gastric	 mucosa	 (6).	 Human	 VEGF-A	 gene	 is	 localized	 in	 the	chromosome	 locus	 6p211.3.	 It	 contains	 eight	 exons	 and	 seven	 introns.	 Alternative	splicing	generates	at	least	seven	VEGF-A	isoforms	having	121,	145,	148,	165,	183,	189	or	206	amino	acids	(Fig.	2).	The	presence	or	absence	of	the	two	exons	influences	protein	solubility	 and	 receptor	 binding,	 as	 they	 encode	 heparin-biding	 domains	 (11).	 VEGF-A	isoforms	 containing	 the	 heparin-biding	 motif	 (HPD)	 encoded	 by	 exon	 6	 (VEGF-A145,	VEGF-A189,	 VEGF-A206)	 interact	 highly	 with	 heparin-containing	 proteoglycans	 in	 the	extracellular	matrix	(ECM).	Instead,	VEGF-A165,	which	is	the	most	abundant	isoform,	is	
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moderately	diffusible,	as	it	contains	only	one	heparin-binding	domain	encoded	by	exon	7.	The	shortest	isoform,	VEGF-A121,	is	a	diffusible	protein,	as	it	lacks	both	exons	necessary	for	encoding	(HPD)	(12,	13).	Plasmin	cleavage	at	the	COOH	terminus	of	higher	molecular	weight	 isoforms	 results	 in	 highly	 diffusible	 fragments.	 Both	 matrix	 binding	 and	proteolytic	release	regulate	the	spatial	distribution	of	VEGF	in	the	tissue	and	allow	the	formation	 of	 extracellular	 VEGF	 gradients	 to	 stimulate	 endothelial	 growth	 (14).	 The	corresponding	mouse	 isoforms	are	one	amino	acid	shorter:	VEGF-A120,	VEGF-A164,	and	VEGF-A188	(15).	The	importance	of	VEGF	gradients	was	demonstrated	in	vivo	in	a	mouse	retinal	 model,	 where	 VEGF-A164	 and	 VEGF-A188,	 which	 bind	 the	 extracellular	 matrix,	facilitate	 EC	 cell	migration	 through	 the	 establishment	 of	 a	 gradient.	 VEGF-A120,	which	represents	the	diffusible	isoform,	induced	random	endothelial	cell	migration	(16).							 	
VEGF-B	 is	 a	 secreted	 homodimer	 abundantly	 expressed	 in	 mice	 during	embryogenesis	in	the	developing	heart,	skeletal	muscles	and	spinal	cord.	Exon	splicing	of	VEGF-B	gene	generates	two	isoforms:	a	form	that	binds	to	cell-surface	heparan	sulfate	proteoglycans	(VEGF-B167)	 and	a	more	diffusible	 form	(VEGF-B186).	VEGF-B	was	 first	considered	as	an	angiogenic	factor;	however,	several	studies	have	demonstrated	a	lack	of	angiogenic	activity.	As	a	matter	of	fact,	VEGF-B	deficiency	or	overexpression	did	not	affect	
Figure	2.	VEGF-A	isoforms.	Alternative	splicing	of	VEGF-A	gene	gives	rise	to	different	isoforms	(Adapted	from	Hiroyuki	T.	et	al,	2005).	
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angiogenesis	in	most	organs	studied.	Recent	studies	have	demonstrated	that	VEGF-B	is	crucial	for	blood	vessel	survival	rather	than	for	stimulating	angiogenesis	(17,	18).		VEGF-C	 and	 VEGF-D	 are	 synthesized	 as	 a	 preproprotein	 and	 proteolytically	process	to	be	activated.	They	are	known	as	lymphangiogenic	factors,	implicated	in	tumor	angiogenesis	and	metastasis	(19).	Orf	virus,	which	is	a	parapoxivirus,	encodes	VEGF-E	to	induce	angiogenesis	in	virus-infected	lesions.	VEGF-E	has	a	similar	propriety	to	that	of	VEGF165	without	the	heparin-binding	domain	(6,	20).	Among	all	VEGFs,	VEGF-A	and	its	receptors	have	been	shown	to	play	a	major	role	in	angiogenesis,	vascular	permeability,	cell	migration	and	gene	expression.			
1.1.2 VEGF	Receptors	VEGF-A	 regulates	 angiogenesis	 and	 vascular	 permeability	 by	 activating	 two	 tyrosine	kinases	 (RTKs)	 (Fig.	3):	VEGFR-1	 (Flt-1)	and	VEGF-R2	 (KDR/Flk1	 in	mice)	 (20).	Each	receptor	consists	of	seven	IgG-like	subdomains	in	the	extracellular	domain,	a	regulatory	juxtamembrane	 domain	 (JMD),	 a	 single	 transmembrane	 (TM)	 region,	 a	 kinase	 insert	domain	(KID)	and	a	consensus	tyrosine	kinase	sequence	which	is	involved	in	recruiting	downstream	signaling	molecules.	VEGFR-1	and	VEGFR-2	are	expressed	predominantly	on	the	cell	surface	of	vascular	endothelial	cells	(Fig.	3).	They	are	also	present	on	many	bone	 marrow-derived	 cells	 such	 as	 hematopoietic	 cells,	 macrophages,	 and	 some	malignant	cells	and	on	vascular	smooth	muscle	cells	(VSMCs)	(21).		VEGFR-1	affinity	for	VEGF-A	is	very	high	with	a	Kd	of	about	15-100	pM,	which	is	higher	than	VEGFR-2.	However,	it	has	a	weaker	tyrosine	kinase	activity.	It	is	expressed	not	only	on	endothelial	cells	but	also	on	the	surface	of	monocytes	where	it	promotes	their	functions.	VEGFR-1	is	also	implicated	in	inflammatory	diseases,	cancer	metastasis,	and	atherosclerosis	via	its	kinase	activity	(22).	Flt-/-	null	mutant	mice	died	in	the	embryonic	
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stage	at	E8.5-9	due	to	an	increased	and	disorganized	vasculature,	suggesting	that	VEGFR-1	plays	 a	 negative	 role	 in	 angiogenesis	 by	 suppressing	pro-angiogenic	 signals	 in	 the	embryo	to	establish	a	critical	balance	essential	for	physiological	vessel	formation	(23).	In	 fact,	VEGFR-1	exists	 as	both	a	 full-length	transmembrane	form	and	a	short	soluble	form	 (sVEGFR1)	 which	 acts	 as	 a	 decoy	 receptor	 for	 VEGF-A	 and	 therefore	 indirectly	inhibits	VEGF-A’s	pro-angiogenic	activities.	VEGFR-2	appears	to	be	the	most	important	receptor	in	VEGF-induced	endothelial	cell	migration	and	proliferation	as	well	as	 in	vessel	permeability	and	dilation.	 It	binds	VEGF-A	with	lower	affinity	but	has	stronger	receptor	tyrosine	auto-phosphorylation.	Flk	knockout	caused	mice	death	in	utero	between	E8.5-9.5	with	no	development	of	a	vascular	system	or	hematopoiesis	(24),	thus	demonstrating	Flk	major	role	in	angiogenesis.	VEGF-C	and	VEGF-D	are	also	ligands	for	Flk	receptor.		VEGFR-3	is	a	typical	tyrosine	kinase	protein	which	binds	only	VEGF-C	and	VEGF-D	and	 its	expression	 is	 limited	to	the	 lymphatic	epithelium	(20).	However,	 it	has	been	reported	 its	 expression	 in	 tumor	 vasculature,	 and	 targeting	 VEGFR-3	 activity	 is	 also	known	to	retard	tumor	formation	by	inhibiting	angiogenesis	(25).		VEGFR	 signaling	 starts	 upon	 biding	 of	 a	 ligand	 dimer	 to	 the	 extracellular	 receptor	domain.	 Ligand	 binding	 induces	 homo-	 or	 hetero-dimerization	 followed	 by	phosphorylation	of	specific	tyrosine	residues	located	in	the	JMD	and	in	the	C-terminal	tail	of	 the	 receptor.	 Consequently,	 different	 signaling	 molecules	 are	 recruited	 to	 VEGFR	dimers,	 giving	 rise	 to	 the	 assembly	 of	 large	 molecular	 complexes—so-called	 signal	transduction	particles	(26).	Src	homology-2	(SH-2)	and	phosphotyrosine-binding	(PTB)	domains	mainly	mediate	 the	 interaction	 between	 VEGFRs	 and	 downstream	 signaling	effectors.	Specifically,	the	biding	between	VEGF-A	and	VEGFR-2	stimulates	the	activation	of	 several	 signaling	 proteins,	 including	 mitogen-activated	 protein	 kinase	 (MAPKs),	
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phosphoinositide	3-kinase	 (PI3K),	phospholipase	C-γ	 (PLC-	γ),	 small	GTPase	and	AKT	(27,	28).	Moreover,	mechanical	forces	(shear	stress)	and	non-VEGF	ligands	can	activate	VEGFR-2	(non-canonical	VEGFR-2	phosphorylation).	Blood	flow	might	activate	VEGFRs	through	the	formation	of	mechanosensory	complexes	that	consist	of	VEGFR-2,	platelet-endothelial-cell	adhesion	molecule-1	(PECAM1,	also	known	as	CD31)	and	VE-cadherin	(Fig.	3).	 Increases	 in	shear	stress	activate	SRC	and	AKT,	resulting	 in	endothelial	nitric	oxide	activation	(eNOS)	and	phosphorylation	of	CD31	and	VEGFR-2	complex	(29).		
	
	
1.1.3 Neuropilins	co-receptors	In	addition	to	the	tyrosine	kinase	receptors,	VEGF	isoforms	binds	with	high	affinity	to	the	neuropilin	(NP)	family	members	NP1	and	NP2	and	to	heparan	sulphate	proteoglycans	to	modulate	VEGFR-2	signaling	(Fig.	3)	(28).	Neuropilins	are	glycoprotein	receptors	with	a	large	extracellular	region	that	is	organized	into	five	domains,	termed	a1,	a2,	b1,	b2,	and	c,	as	well	as	a	single	pass	transmembrane	domain	and	a	short	cytoplasmic	domain	of	40	
Figure	3.	VEGF	family	members	and	receptors.		Schematic	representation	of	VEGF	ligands	(VEGFA:	light	green,	VEGFC	or	D:	dark	green)	and	their	receptor	tyrosine	kinases	VEGFR-1,	VEGFR-2	and	VEGFR-3.	VEGFR2	can	homodimerize	or	heterodimerize	with	VEGFR1	or	3.	Ligand	binding	results	 in	receptor	phosphorylation	of	 tyrosine	residues	 in	 the	intracellular	domain,	which	induces	different	biological	outcomes.	VEGFR2	signaling	can	be	modulated	through	co-receptors	 binding.	 VEGFR	 has	 several	 co-receptors	 including	 heparan	 sulfate	 (HS)	 proteoglycans,	 neuropilins	(NRPs),	vascular	endothelial	cadherin	(VE-cadherin),	integrins,	ephrin	B2	and	protein	tyrosine	phosphate	(PTP)	(Adapted	from	Simons	M.	et	al,	2016).	
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residues	 (30).	 In	 humans,	 the	 two	 proteins	 show	 44%	 identity	 (31).	 NPs	 were	 first	identified	as	receptors	of	class-3	semaphorins	(Sema3),	which	are	a	family	of	secreted	and	membrane	 proteins	with	 neuronal	 guidance	 functions.	 Several	 studies	 have	 also	shown	that	NPs	have	a	critical	role	in	the	development	of	the	vascular	system	(32).	During	development,	NP1	is	highly	expressed	on	the	endothelial	cells	of	capillaries,	arteries	and	veins	in	postnatal	mouse	retina	and	in	growing	vessels	in	the	mouse	embryo	hindbrain	on	 day	 E11.5	 (33).	 Many	 studies	 have	 demonstrated	 the	 importance	 of	 NP1	 in	angiogenesis.	For	instance,	the	overexpression	of	this	receptor	in	mouse	embryos	leads	to	an	excessive	growth	of	leaky	and	hemorrhagic	vessels	(34).	In	contrast,	NP-1	null	mice	died	in	utero	due	to	reduced	vessel	sprouting,	especially	in	the	brain	and	spinal	cord.	They	also	experienced	severe	cardiovascular	defects	(35).		NP2	interacts	with	VEGF-A,	VEGF-C	and	VEGF-D.	Its	signaling	is	also	important	for	VEGF-C/VEGFR-2/R-3-mediated	 lymphangiogenesis	 (36).	 Conversely,	 NP1	 binds	 the	heparin-binding	 isoforms	 of	 VEGF-A,	 VEGF-B	 and	 PIGF.	 It	 has	 a	 relatively	 short	cytoplasmic	tail	with	no	known	catalytic	activity,	suggesting	that	NP1	needs	a	co-receptor	to	transduce	signals	in	the	vasculature	(37).	In	endothelial	cells,	the	candidates	for	NP1	signal	transduction	are	VEGFR-1	and	VEGFR-2,	as	both	have	been	shown	to	interact	with	NRP1	in	vitro	(33).	Moreover,	 immunoprecipitation	studies	reveal	 that	NP1	 interacted	with	VEGF-A165	and	not	with	VEGF-A121,	suggesting	that	 the	binding	to	the	receptor	 is	mediated	via	the	exon	7-encoded	region	of	VEGF	which	is	absent	in	VEGF-A121.	However,	VEGF-A165	binds	its	receptors	VEGFR-1	and	VEGFR-2	via	exon	3	and	4,	respectively	(38).	Therefore,	it	was	suggested	that	NP1	enhances	VEGF	biding	by	forming	a	bridge	between	NP1	and	VEGFRs.	Additionally,	the	interaction	between	VEGF-A165,	NP1	and	VEGFR-2	can	occur	in	cis	when	both	receptors	are	present	on	the	same	endothelial	cells	or	in	trans	if	VEGFR-2	is	expressed	by	endothelial	cells	and	NP1	is	present	on	another	nearby	cell	(39).	
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The	 cis	 configuration	 allows	 a	 rapid	 VEGFR-2/NP1	 complex	 formation	 and	internalization	 where	 biding	 in	 trans	 delays	 complex	 formation,	 therefore	 inhibiting	angiogenesis.	 NP1	 therefore	 has	 an	 important	 role	 in	 regulating	 VEGFR	 trafficking	affecting	VEGF	signaling	and	angiogenesis	(29).			
1.2 Cellular	Mechanism	of	Angiogenesis	Angiogenesis	is	the	growth	of	blood	vessels	from	the	existing	vascular	bed.	There	are	two	main	 cellular	mechanisms:	 sprouting,	 and	 intussusceptive	angiogenesis.	Both	occur	 in	utero	and	in	adults.	As	its	name	suggests,	sprouting	angiogenesis	involves	the	formation	of	 endothelial	 sprouts	 that	 grow	 towards	 an	 angiogenic	 gradient.	 In	 contrast,	intussusceptive	angiogenesis	is	called	splitting	angiogenesis	because	an	existing	vessel	splits	into	two	new	ones	(40).		
1.2.1 Sprouting	angiogenesis	Sprouting	angiogenesis	can	be	divided	 in	several	key	phases:	activation	of	endothelial	cells	 (ECs)	 by	 pro-angiogenic	 stimuli,	 capillary	 basement	 membrane	 degradation,	endothelial	cell	proliferation	and	migration,	tube	formation,	vessel	pruning	and	pericyte-mediated	vessel	stabilization	(41).	Endothelial	cells	and	mural	cells	are	embedded	within	the	 basement	membrane;	 therefore,	 ECs	must	 be	 liberated	 in	 order	 to	migrate.	 Upon	endothelial	 cell	 activation,	 cell-cell	 junctions	 and	 the	 basement	 membrane	 (BM)	 are	degraded	by	matrix	metalloproteases	(MMPs)	such	as	MT-	MMP1	in	tandem	with	mural	cells	detachment,	allowing	EC	tip	cells	to	migrate	in	response	to	guidance	signals	(42).	Ang2,	a	proangiogenic	factor	stored	in	endothelial	cells,	is	rapidly	released	to	stimulate	pericytes	detachment.		
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Tip	cells	are	endothelial	cells	with	migratory	capacity	characterized	by	numerous	filopodia	extensions	to	sense	VEGF	gradient	in	the	surrounding	extracellular	matrix	(Fig.	4).	In	contrast,	the	neighboring	ECs,	called	stalk	cells,	are	more	proliferative	and	thus	act	as	building	blocks	for	the	nascent	sprout	(41,	43).	VEGF	and	Notch	signaling	pathways	are	responsible	for	the	specification	of	a	tip	and	stalk	cells	in	the	vascular	endothelium	(Fig.	4).	In	mammals,	there	are	four	Notch	receptors	(Notch1-4)	and	five	ligands,	Jagged-1	and	2	and	Delta-like	proteins	(Dll1,	Dll3	and	Dll4).	Notch	receptors	are	large	single-pass	type	I	transmembrane	proteins	and	most	of	the	Notch	ligands	are	also	themselves	type	I	transmembrane	proteins.	Therefore,	Notch	signaling	is	mediated	by	cell-cell	interaction	and	can	happen	in	cis	(in	the	same	cell)	or	in	trans	(different	cells)	(44).	The	interaction	between	Notch	receptors	and	ligands	triggers	a	series	of	proteolytic	cleavages	that	result	in	 the	 release	 of	 the	 active	 Notch	 intracellular	 domain	 (NCID).	 Afterward,	 NCID	translocate	to	the	nucleus,	where	it	activates	the	expression	of	target	genes	(43).											
Figure	 4.	Phases	 of	 tip	 cell	 selection	 during	 sprouting.	 During	 angiogenesis,	 ECs	 extend	 filopodia	 and	migrate	towards	an	angiogenic	gradient.	Endothelial	cells	can	become	either	migratory	(tip	cells)	or	proliferating	cells	(stalk	cells).	VEGF	and	Notch	signaling	are	involved	in	the	specification	of	tip/stalk	cells.	Activated	ECs	compete	for	the	tip	cell	position	by	up-regulating	Dll4,	which	activates	notch	signaling	in	the	neighboring	ECs.	Dll4/Notch	signaling	activation	down-regulates	 VEGFR-2	 while	 up-regulating	 VEGFR-1.	 Jagged-1	 expresses	 by	 stalk	 cells	 antagonized	 Dll4/Notch	signaling	in	the	migratory-leading	cell.	In	addition,	Notch	is	modified	by	Fringe.	This	differential	Notch	activity	allows	the	specification	between	tip	and	stalking	cells	(Adapted	from	Blanco	R.	et	al.,	2013).	
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Dll4	signaling	through	Notch1	receptors	regulates	the	formation	of	endothelial	tip	cells	to	control	vessel	sprouting.	Loss	of	Dll4	or	Notch	function	leads	to	an	over-sprouting	due	to	an	excessive	formation	of	tip	cells.	Conversely,	the	activation	of	Notch	signaling	causes	a	less	dense	vascular	network	as	a	result	of	a	reduced	number	of	tip	cells	(45).	During	 sprouting	 angiogenesis,	 VEGF	 interacts	 with	 VEGFR-2	 and	 stimulates	 tip	 cell	induction	 and	 filopodia	 formation,	 and	 it	 promotes	 Dll4	 expression	 in	 tip	 cells.	 Dll4	activates	 Notch1	 in	 neighboring	 stalk	 cells,	 inhibiting	 tip	 cell	 behavior	 in	 these	 cells	through	the	down-regulation	of	VEGFR-2	while	up-regulating	VEGFR1.	Consequently,	tip	cells	 have	 a	 higher	 expression	 of	 Dll4	 while	 stalk	 cells	 have	 high	 Notch-signaling	activation	and	lower	expression	of	VEGFR-2	(Fig.	4).	The	Notch	and	VEGF	feedback	loop	allows	a	stable	pattern	of	tip	and	stalking	cells.	Moreover,	endothelial	cells	that	express	Dll4	at	higher	 levels	or	more	quickly	have	a	reasonable	advantage	to	become	tip	cells	(46).	 In	 contrast	 to	Dll4,	 Jagged-1	signaling	antagonized	Dll4-Notch	activation	 in	stalk	cells	to	support	tip	cell	selection	and	sprouting	(Lateral	Inhibition).	The	activity	of	the	two	ligands	is	controlled	by	the	modification	of	Notch	receptors	by	the	Fringe	family	of	glycosaminyltransferases,	 which	 has	 been	 shown	 to	 repress	 Jagged-1	 binding	 and	enhance	Dll4-Notch	signaling	(47).	In	developing	mouse	retina,	VEGFR-3	expression	is	higher	in	tip	cells	compared	with	stalk	cells.	Additionally,	the	activation	of	VEGFR-3	by	VEGF-C	in	tip	cells	increases	Notch	signaling,	thus	promoting	tip	to	stalk	conversion	(48).	Tip	cells	express	guidance	receptors	including	ROBO4,	UNC5B,	PLEXIN-D1,	NRPs	and	Ephrin	family	members	that	favor	the	guidance	of	the	new	sprout	(49).		Continued	sprouting,	branching,	and	tubulogenesis	(anastomosis)	are	required	to	expand	the	vasculature,	and	lumen	formation	is	a	critical	step	in	the	development	of	a	new	vascular	network.	Anastomosis	can	occur	between	sprouts	of	two	tip	cells	(‘head-to-
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head’	anastomosis)	or	between	a	tip	cell	sprout	and	a	functional	vessel	(‘Head-to-side’	anastomosis)	 (41).	 Mural	 cells	 are	 then	 recruited	 by	 platelet-derived	 growth	 factor	(PDGF-BB)	 expressed	 by	 endothelial	 cells.	 Mural	 cells	 reduce	 endothelial	 cell	proliferation	 and	 migration.	 The	 establishment	 of	 a	 new	 blood	 flow	 allows	 vessel	remodeling,	which	is	regulated	by	the	shear	stress-responsive	transcription	factor	KLK2.	Autocrine	 signals,	 including	VEGF,	 Angiopoietin-1	 and	Notch	 promote	 endothelial	 cell	quiescence,	thereby	stabilizing	nascent	vessels	(42).			
1.3.2.	 Intussusception	angiogenesis	Intussusceptive	 angiogenesis	 (IA)	 is	 a	 mechanism	 of	 vascular	 growth	 in	 which	 the	capillary	network	expands	“within	itself.”	It	was	discovered	about	two	decades	ago	in	the	developing	lungs	of	neonatal	rats	(50).	The	process	of	intussusceptive	angiogenesis	can	be	divided	in	four	steps:	I)	invagination	of	the	capillary	walls	into	the	lumen	until	contact	is	 made	 by	 transluminal	 endothelial	 protrusion;	 II)	 rearrangement	 of	 the	 inter-endothelial	junctions	and	central	core	perforation	of	the	endothelial	pillar,	this	phase	is	characterized	by	the	formation	of	a	cylindrical	tissue	bridge	wrapped	by	ECs;	III)	pillar	invasion	 by	 pericytes	 and	myofibroblast	 and	 extracellular	matrix	 deposition;	 and	 IV)	pillar	enlargement	and	fusion	resulting	in	the	splitting	of	the	initial	capillary	into	to	new	capillaries	(Fig.	5)	(51).		Tissue	pillar	formation	is	the	hallmark	of	intussusceptive	angiogenesis;	however,	depending	 on	 the	 arrangement	 and	 direction	 of	 the	 pillars,	 three	 forms	 of	 IA	 can	 be	recognized:	 I)	 intussusceptive	 microvascular	 growth	 (IMG);	 II)	 intussusceptive	arborization	 (IAR);	 and	 III)	 intussusceptive	 branch	 remodeling	 (IBR).	 IMG	 was	 first	identified	in	the	lung	vasculature	of	postnatal	rats	and	subsequently	in	their	myocardium,	skeletal	muscles,	kidneys	and	retinas	(52).	The	IMG	process	leads	to	an	extension	of	the	
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existing	vasculature	through	the	continuous	formation	and	expansion	of	new	pillars	in	the	vascular	network.	It	has	been	suggested	that	IMG	is	driven	by	blood	flow,	resulting	in	a	network	of	capillaries	of	similar	size	(53).	IAR,	on	the	other	hand,	contributes	to	the	enlargement	of	the	vascular	tree	through	the	formation	of	smaller	vessels.	During	IAR,	favorably-perfused	 capillaries	 can	 be	 transformed	 into	 terminal	 arterioles	 and	collecting	venules	by	changing	size	and	position	to	form	a	new	vascular	entity.	The	third	form	of	IA,	IBR,	is	the	mechanism	that	adjusts	the	number	of	vessels	to	efficiently	supply	a	tissue	with	a	proper	vasculature	by	either	remodeling	the	branching	pattern	of	blood	vessels	 or	 pruning	 the	 vascular	 network	 from	 unnecessary	 vessels	 (50,	 54).	 Thus,	 IA	occurs	in	pre-existing	vascular	networks	formed	by	either	vasculogenesis	or	sprouting.	During	normal	cardiovascular	development	in	an	embryo,	the	majority	of	the	developing	vessels	arise	through	SA	and	then	IA	takes	place	(53,	55).	During	IA,	in	contrast	with	SA,	the	 basement	 membrane	 stays	 intact,	 and	 endothelial	 proliferation	 and	 migration	 is	reduced	as	the	ECs	instead	increase	in	size	and	flatten	to	proliferate	(56).			Blood	flow	and	shear	stress	play	an	important	role	during	IA.	The	endothelium	responds	rapidly	and	sensitively	to	the	mechanical	conditions	created	by	blood	flow.	Shear	stress	is	defined	as	the	tangential	force	of	the	flowing	blood	on	the	endothelial	surface	of	the	vascular	wall.	 Laminar	shear	stress	promotes	endothelial	 cell	survival	 and	quiescence	and	alignment	in	the	direction	of	flow.	In	contrast,	turbulent	or	oscillatory	shear	stress	promotes	endothelial	proliferation	and	migration—a	process	characteristic	of	SA	(57).	The	regulation	of	intussusceptive	angiogenesis	by	hemodynamics	was	demonstrated	in	the	developing	 chick	CAM	vasculature	 (58).	An	artificial	 increase	 in	blood	 flow	 in	 the	cognate	 artery	 by	 clamping	 one	 of	 the	 branches	 resulted	 immediately	 in	 branching	morphology	 and	 pillar	 formation.	 Based	 on	 in	 vivo	hemodynamic	 parameters	 and	 3D	computational	models,	it	was	calculated	that	transluminal	pillar	development	occurred	
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in	the	areas	characterized	by	low	shear	and	turbulent	flow	conditions	(59).	This	suggests	that	changes	in	the	hemodynamics	of	blood	flow	cause	an	immediate	vascular	adaptation	(60).	Apart	from	hemodynamic	factor,	IA	can	also	be	regulated	by	molecular	mechanisms.	However,	limited	data	are	available	on	the	molecular	mechanism	governing	IA	due	to	the	lack	 of	 proper	 experimental	 assays.	 In	 our	 group,	we	 recently	 demonstrated	 that	 the	over-expression	of	VEGF164	in	the	skeletal	muscles	resulted	in	the	formation	of	vascular	enlargement	followed	by	transluminal	pillar	formation	and	intussusceptive	longitudinal	remodeling	(Roberto	Gianni	Barrera,	in	preparation).									
					
Figure	5.	Mechanism	of	pillar	formation	during	IA.	Scheme	illustrating	the	phases	in	the	formation	of	transluminal	pillars	(a-d).	During	IA,	endothelial	cells	from	the	opposite	sides	protrude	into	the	lumen	until	a	contact	is	established.	After	the	contact	has	been	established,	the	central	core	of	the	endothelial	bilayer	is	perforated	to	form	a	transluminal	pillar.	2D	representation	of	the	events	described	above	(Adapted	from	Makanya	A.N.	et	al.,	2009).		
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II. Vascular	Maturation	and	Stabilization	
The	maturation	of	newly-formed	capillaries	is	a	late	event	in	the	angiogenic	process.	This	process	is	a	crucial	step	in	achieving	a	functional	vascular	network.	It	involves	pericyte	recruitment,	 deposition	 of	 the	 extracellular	 matrix,	 endothelium	 cell	 quiescence	(endothelial	phalanx	phenotype)	and	an	increased	formation	of	cell	junctions	(42).	Active	endothelium	is	easily	susceptible	to	regression	on	withdrawal	of	growth	factors,	whereas	mature	vessels	are	more	resistant	(61).	An	increase	in	blood	flow	and	oxygen	delivery	promotes	 vessel	 maturation	 and	 stabilization.	 Vessel	 maturation	 leads	 to	 vascular	stabilization—a	 state	 in	 which	 newly-induced	 vessels	 are	 provided	 with	 structural	support,	mechanical	resistance	and	reduced	endothelial	cell	demand	for	soluble	survival	factors,	such	as	VEGF	(62).		
2.1 Pericyte-mediated	vessel	maturation	and	stabilization	Vessel	maturation	is	characterized	by	a	dynamic	interaction	between	ECs,	mural	cells	and	soluble	factors	including	PDGF-BB,	transforming	growth	factor	β	(TGF-β1),	angiopoietin	1	(Ang1)	and	the	extracellular	environment.	During	vessel	maturation	and	stabilization,	TGF-β1	promotes	the	differentiation	of	precursor	cells	in	pericytes	(Fig.	6)	(63),	which	then	migrate	towards	PDGF-BB	expressed	by	endothelial	cells.	Ang1	it	has	been	shown	to	 favor	 pericyte	 recruitment	 on	 nascent	 vessels	 (64).	 Sphingosine-1-phosphate	expressed	by	pericytes	(S1PR)	modulates	EC/pericyte	cell	interactions	by	up-regulating	N-cadherin	between	ECs	and	pericytes	while	down-regulating	the	destabilizing	protein	Ang2.	 Finally,	 basement	 membrane	 (BM)	 is	 deposited	 and	 cell-junctions	 are	 re-established	to	ensure	ideal	blood	flow	through	the	new	vessels	(62).	
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2.1.	1	 Pericyte	biology	Pericytes	are	mural	cells	of	 the	microcirculation	which	are	known	to	play	key	roles	in	regulating	microvascular	morphogenesis	 and	 stability	 in	 different	 tissues	 and	 organs	(65).	 Pericytes	were	 first	 described	more	 than	 100	 years	 ago	 by	Benjamin	Rouget	 as	perivascular	 contractile	 cells	 surrounding	 blood	 capillaries	 (66).	 Electron-microscopy	analysis	 helped	 to	 elucidate	 their	 morphology.	 In	 general,	 mature	 pericytes	 are	
Figure	6.	Signaling	pathways	mediating	endothelium-Pericyte	cross	talk.	 	Several	factors	acting	in	an	autocrine	and/or	paracrine	manner	are	involved	in	vascular	maturation	and	stabilization:	PDGF-B/PDGFR-β,	Ang1/Tie2,	TGF-	β/activin	 receptor-like	 kinase	 1	 and	 5	 (ALK1	 and	ALK5).	 Notch	 and	 N-cadherin	 signaling	 requires	 direct	 contact	between	cells	(Adapted	from	Armulik	A.	et	al,	2011).	
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considered	cells	with	a	fattened	or	stellate-shape	with	multiple	long	processes	attached	to	the	abluminal	side	of	the	vessels	embedded	within	the	vascular	basement	membrane	(BM)	 (67).	 Pericytes	 are	 ubiquitously	 present	 in	 blood	 capillaries,	 arterioles,	 post-capillaries	 and	 collecting	 venules,	 but	 not	 in	 lymphatic	 capillaries	 (68).	 In	 contrast	 to	small	vessels,	larger	blood	vessels	are	covered	with	single	or	multiple	layers	of	smooth	muscle	cells	(vSMCs).	The	abundance	of	pericytes	varies	based	on	tissue	and	vessel	size.	The	 highest	 density	 (endothelial	 cell-pericyte	 ratio	 1:1)	 is	 present	 in	 neural	 tissues,	especially	 in	 retina.	 In	 general,	 pericytes	 are	 more	 extensively	 present	 in	 venous	capillaries	and	post-capillary	venules	(69).	Pericytes	typically	cover	from	10%	to	70%	of	the	abluminal	surface	of	the	endothelium	(66).		Due	 to	 their	 heterogeneity,	 there	 are	 many	 molecular	 markers	 for	 pericytes.	However,	these	markers	cannot	be	used	unequivocally	to	distinguish	them	from	vSMC	or	other	Mesenchymal	cells	(67).	Commonly-used	pericyte	markers	include	neuron-glial	2	(NG2),	desmin,	vimentin	and	PDGFRβ.	Pericytes	on	normal	capillaries	express	desmin	but	not	alpha	smooth-muscle	actin	(α-SMA),	whereas	pericytes	from	venules	are	positive	for	both	(70).	The	expression	pattern	of	these	markers	is	tissue	specific	and	dependent	on	the	development	stage	of	the	blood	vessels.	Different	types	of	surface	cell	contact	are	present	 between	 endothelial	 cells	 and	 pericytes.	 Ultrastructural	 studies	 have	demonstrated	 the	 presence	 of	 peg-socket	 contacts	 formed	 by	 pericytes’	 cytoplasmic	fingers,	which	invaginate	into	the	endothelium	(71).	In	addition,	pericytes	and	ECs	can	connect	their	cytoskeletons	with	cadherins	through	cytoplasmic	membranes.	Cadherins	and	gap	junctions	between	their	cytoplasms	also	allow	the	passage	of	metabolites	and	ionic	currents	(67,	72).	Similar	to	vSMC,	pericytes	might	have	different	origins.	In	fact,	pericytes	 from	 the	 central	 nervous	 system	 and	 thymus	 originate	 from	 the	 ectoderm-derived	neural	crest,	whereas	pericytes	present	in	coleomics	have	a	mesothelium	origin	
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(67).	During	angiogenesis,	PDGF-B/PDGFRβ	paracrine	signals	have	a	key	role	in	pericyte	recruitment	(73).	
2.1.2		 PDGF-BB/PDGβR	signaling	
2.1.2.1	PDGF	and	PDGFR	Family	During	 vessel	 sprouting,	 activated	 endothelial	 cells	 release	 PDGF-BB	 to	 chemoattract	PDGF	receptor-b+	pericytes	(62).	Platelet-derived	growth	factors	(PDGFs)	are	important	mitogen	 for	many	 types	of	 cells	 of	mesenchymal	 origin,	 including	 fibroblasts,	 smooth	muscle	 cells	 and	 pericytes	 and	 for	 neuroectodermal	 derived	 cells	 including	oligodendrocytes	(74).		The	PDGF	family	is	composed	of	four	polypeptide	chains:	PDGF-A,	PDGF-B,	PDGF-C	and	PDGF-D.	Genes	located	on	chromosomes	7,	22,	4,	and	11	(pdgfa,	pdgfb,	pdgfc	and	
pdgfd)	respectively	encode	each	chain.	All	PDGFs	can	form	homodimers,	whereas	PDGF-A	 and	 PDGF-B	 can	 also	 heterodimerize	 (66).	 All	 PDGFs,	 like	 VEGFs,	 have	 a	 highly-conserved	homology	domain	with	a	length	of	approximately	100	amino	acids	which	is	primarily	 responsible	 for	 recruiting	 receptors.	 The	 domain	 is	 a	 cysteine-knot	 motif	involved	 in	 intra-	and	 inter-disulphide	bonding	of	 the	dimers	(75).	PDGF	 isoforms	are	produced	 as	 inactive	 precursors	 in	 which	 specific	 PDGF-	 A	 and	 PDGF-B	 pro-peptide	sequences	 are	 cleaved	 intracellularly	 by	 furin-like	 proteases	 to	 form	 mature	 growth	factors.	Conversely,	PDGF-C	and	PDGF-D	are	secreted	in	a	latent	form	characterized	by	the	presence	of	a	CUB	domain	in	the	N-terminal	(Fig.	7).	The	CUB	domain	is	a	structural	motif	of	approximately	110	residues	found	in	many	different	kinds	of	proteins,	including	numerous	extracellular	proteases,	some	components	of	the	complement	cascade	and	cell	surface	proteins	(76).	PDGF-C	and	PDGF-D	are	activated	by	limited	proteolysis	of	the	CUB	domain.	Thus,	 the	principal	role	of	 the	CUB	domain	 is	 to	 interfere	with	ligand	binding	
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with	 receptors	 (74).	 PDGF-A	 and	PDGF-B	C-terminuses	 are	 rich	 in	 positively-charged	amino	acids	which	are	 involved	 in	the	retention	and	distribution	of	growth	factors	by	binding	heparin	and	heparin	sulfate	proteoglycans	(77).	The	PDGF-A	tail	is	lost	in	a	short	isoform	by	alternative	splicing.	PDGF-C	and	PDGF-D	lack	the	tail	necessary	 for	growth	factor	retention;	however,	their	CUB	domain	may	regulate	the	extracellular	distribution	of	the	latent	from	of	the	growth	factors	(75).	During	embryonic	development,	epithelial	cells	 produce	 PDGF-A,	 whereas	 PDGF-B	 is	 expressed	 mainly	 in	 the	 developing	vasculature	 by	 endothelial	 cells.	 PDGF-C	 is	 expressed	 in	 many	 cell	 types	 during	embryogenesis,	 including	mesenchymal	 precursors,	 vascular	 smooth	muscle	 cells	 and	cells	of	the	central	nervous	system	(74),	while	PDGF-D	has	been	reported	to	be	expressed	in	kidneys	(78).		PDGF	 is	 a	 potent	 chemoattractant	 and	 has	 been	 involved	 in	 bone	 formation,	erythropoiesis,	wound	healing	and	angiogenesis.	 It	 is	also	 implicated	 in	tumor	growth	and	in	the	formation	of	lesions	in	inflammatory	diseases	and	atherosclerosis	(79).	PDGF	signals	 through	 two	 PDGFRs—PDGFRa	 and	 PDGFRb—to	 stimulate	 cell	 proliferation,	migration	 and	 angiogenesis.	 PDGF	 isoforms	 have	 the	 distinct	 ability	 to	 bind	 to	 PDGF	receptors.	PDGF-AA,	PDGF-AB,	PDGF-BB	and	PDGF-DD	can	bind	and	activate	PDGFRa	whereas	PDGF-BB	and	PDGF-AB	can	bind	to	and	activate	PDGFRb	(Fig.	7).	In	addition,	PDGF-AB,	PDGF-BB	and	PDGF-CC	can	stimulate	the	heterodimer	PDGFRa/b	(Fig.	7)	(74).	The	two	PDGFRs	belong	to	the	class	III	receptor	tyrosine	kinase	(RTKs),	a	family	of	 five	 members	 including	 colony-stimulating	 factor-1	 receptor	 (CSF-1R),	 Fms-like	tyrosine	 kinase	 (FLT3)	 and	 the	KIT	 receptor	 tyrosine	 kinase.	 The	 PDGFR	 and	VEGFR	families	 are	 evolutionarily	 related.	 PDGFRs	 have	 a	 common	 domain	 structure	characterized	by	five	immunoglobulin	(Ig)-like	domains	in	the	extracellular	segment	that	
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function	in	ligand	binding	(D1-D3)	and	receptor	dimerization	(D4).	In	addition,	PDGFRs	have	a	single	transmembrane	helix	and	an	intracellular	tyrosine	kinase	domain	(80).			
			PDGF	 dimer	 binds	 the	 receptor	 at	 Ig	 domains	 D2	 and	 D3	 and	 promotes	 receptor	dimerization	(homo-	or	heterodimerization),	which	is	then	stabilized	by	direct	receptor-receptor	 interaction	with	 the	D4	and	D5	domains	 (75).	Once	dimerization	occurs,	 the	intracellular	domain	undergoes	autophosphorylation	in	trans	between	the	receptors	in	the	 dimers.	 PDGFRa	 and	 PDGFRb	 have	 10	 and	 11	 autophosphorylation	 sites,	respectively.	The	autophosphorylation	of	certain	tyrosine	kinase	has	two	main	functions:	(I)	it	promotes	receptor	activation	by	conformational	changes	of	the	intracellular	parts,	and	 (II)	 it	 causes	 subsequent	 recruitment	of	 SH-domain-containing	 signaling	 proteins	(81).	 Finally,	 receptor	 activation	 promotes	 cellular	 responses	 like	 proliferation	 and	migration.			
Figure	7.	PDGF/PDGFR	signaling.	PDGF-A	and	PDGF-B	are	secreted	as	active	homo-	or	heterodimers,	while	PDGF-C	 and	 PDGF	 -D	 need	 proteolytical	 cleavage	 of	the	CUB	domain	to	bind	their	receptors.	Plasmin	can	activate	both	PDGF-C	and	PDGF–D,	whereas	the	tissue	plasminogen	 activator	 (tPA)	 is	 specific	 for	 PDGF-C.	Ligand	 binding	 to	 receptors	 results	 in	 receptor	dimerization,	 autophosphorylation	and	activation	 of	different	 pathways,	 including	 janus	 kinase	 (JAK)/	signal	 transducers	 and	 activators	 of	 transcription	(STAT),	 phosphatidyl-inositol-3-kinase	 (PI3K),	phospholipase	C-γ	RAS	(PLC-γ)	or	mitogen-activated	protein	kinase	(MAPK)	pathways.	These	pathways	are	involved	in	cell	migration,	proliferation	and	survival	(Adapted	from	Ostendorf	T.	et	al,	2014).	
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2.1.2.1	PDGF-BB/PDGFRb	signaling	during	blood	vessel	formation	During	 angiogenesis,	 PDGF-BB	 and	 PDGFRb	 play	 an	 important	 role	 in	 pericyte	recruitment	to	newly-induced	blood	vessels.	PDGF-BB	is	release	at	higher	levels	by	tip	cells	 when	 compared	 to	 stalk	 cells.	 Once	 secreted,	 PDGF-BB	 strongly	 binds	 the	extracellular	matrix-forming	steep	gradients,	allowing	a	proper	recruitment	of	pericytes.	As	a	consequence,	pericytes	stabilize	the	nascent	vessels	through	paracrine	signals	(67,	82).	 The	 role	 of	 PDGF-BB/	 PDGFRb	 is	 supported	 by	 several	 knockout	 experiments.	Knockout	of	pdgfb	or	pdgrb	in	mice	is	lethal	at	the	embryonic	stage	due	to	widespread	microvascular	defects	consisting	of	vessel	dilatations,	microaneurisms,	excessive	luminal	folds	and	 lack	of	pericyte	recruitment.	The	 failure	to	recruit	PDGFRb-positive	pericyte	progenitors	leads	to	vascular	instability	and	regression	(70).	Moreover,	deletion	of	the	PDGF-BB	retention	motif	 in	mice	(necessary	 for	pericyte	adhesion)	results	 in	pericyte	detachment	 from	 the	microvessels,	 suggesting	 that	 PDGF-BB	 retention	 is	 an	 absolute	recruitment	for	pericyte	recruitment	and	organization	of	nascent	vessels	(83).			
2.1.3		 Angs/Tie	signaling	
2.1.3.1	Ang1	and	Ang2	ligands	and	Tie	receptors	Normal	vessels	must	have	mechanisms	for	maintaining	endothelium	quiescence	while	simultaneously	 remaining	 able	 to	 respond	 to	 angiogenic	 stimuli.	 In	 this	 context,	angiopoietins	(Angs)	and	Tie	 family	 is	a	dual	system	which	allows	such	a	switch	(62).	Angiopoietins	are	a	 family	of	secreted	multimeric	proteins	which	collaborate	with	the	VEGF	family	to	regulate	vascular	and	lymphatic	vessel	growth	through	endothelial	Tie2	receptors	(84).	
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The	Angs	 family	 comprises	 three	members:	Ang1,	Ang2	and,	 in	humans,	Ang4.	Mouse	Ang3	and	human	Ang4	are	orthologous;	both	represent	the	third	member	of	this	family	 (85).	 Ang1	 and	 Ang2	 are	 the	 best-characterized	 ligand	 of	 the	 family	 and	 their	proteins	share	60%	of	their	amino	acid	identity	(86).	Angiopoietins	are	characterized	by	the	presence	of	a	short	amino-terminal	domain	which	promotes	clustering	of	molecules	followed	 by	 a	 coiled-coil	 motif	 that	 supports	 multimerization.	 The	 carboxy-terminal	fibrinogen	 domain	 contains	 the	 binding	 sites	 for	 Tie2	 receptors.	 Angs	 homodimeric	multimers	are	composed	of	three	to	six	individual	ligands	(87).	The	multimerization	of	the	 ligands	 is	 crucial	 to	 activate	 Tie2	 in	 the	 endothelium.	 Ang1	 was	 the	 first	 ligand	discovered	for	Tie2	expressed	by	perivascular	cells.	It	is	stored	at	high	levels	in	platelet	granules	(87,	88).	Ang2	 is	expressed	mostly	by	activated	endothelial	cells	and	also	by	smooth	muscle	 cells.	 This	 protein	 is	 expressed	 in	 cytoplasmic	 storage	 granules	 called	Weibel-Palade	 bodies	and	 is	 rapidly	 released	after	 stimulation	with	different	agonists	including	VEGF,	angiotensin	II,	thrombin	and	leptin	(89).	The	receptors	tyrosine	kinase	Tie1	and	Tie2	constitute	a	particular	RTK	subfamily	with	a	unique	extracellular	structure	consisting	of	two	Ig	domains	followed	by	three	EGF-like	domains,	one	more	Ig	motif	and	three	fibronectin	type	III	domains.	Both	receptors	have	split	tyrosine	kinase	domains	in	the	intracellular	portion	(90).		Endothelial	 cells	 express	 Tie2;	 however	 this	 expression	 has	 also	 been	demonstrated	 in	subtypes	of	monocytes	and	macrophages	 (91).	 In	normal	 conditions,	Tie2	binds	directly	to	angiopoietins	and	has	a	strong	kinase	activity,	whereas	Tie1	does	not	bind	directly	and	has	a	weak	kinase	activity.	The	binding	between	angiopoietins	and	Tie2	 receptors	 causes	 Tie2	 receptor	 clustering.	 Ang1	 and	 Tie2	 interaction	 induces	receptor	phosphorylation	on	tyrosine	kinase	residues,	which	results	in	the	activation	of	several	 downstream	pathways	 like	 PI3-kinase/Akt	 and	ERK.	 In	 cell-matrix	 or	 cell-cell	
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contacts,	the	complexes	of	Ang1/Tie2	can	interact	with	Tie1,	resulting	in	the	activation	of	the	receptor	in	order	to	stabilize	the	endothelium	or	stimulate	endothelial	migration,	respectively	(92).			
2.1.3.1	The	Ang-Tie	signaling	system	in	vessel	development	The	interaction	between	angiopoietins	and	Tie2	receptors	plays	an	important	role	during	endothelial	sprouting,	pericyte	recruitment	and	vessel	remodeling	(Fig.	8)	(70).	Loss	of	function	 experiments	 have	 contributed	 to	 defining	 the	 role	 of	 angiopoietins	 and	 Tie	receptors	during	vascular	development	and	vascular	remodeling.	Ang1	or	Tie2	knockout	in	mouse	 embryos	was	 lethal	 at	E10.5	 and	 12.5	 respectively	 due	 to	 severe	 heart	 and	vascular	 defects.	 The	 vessels	 present	 in	 Ang1-null	 embryos	 lack	 proper	 pericyte	attachments	 and	 therefore	 fail	 to	mature	 (93).	 In	 the	Tie2-deficent	mice,	 the	 primary	capillary	plexus	fails	to	remodel,	and	it	remains	not	well	organized	with	few	endothelial	cells	and	breaches.	Interestingly,	Tie1-null	mice	died	later	during	development	because	of	 a	 lack	 of	 vessel	 integrity	 (edema)	 without	 perturbation	 of	 angiogenesis.	 In	 Ang2-deficient	 mice,	 vascular	 development	 was	 not	 perturbed.	 This	 has	 consequently	facilitated	the	study	of	the	protein	in	adult	mice.	However	adult	Ang2-deficient	mice	have	vascular	defects	(94).	Transgenic	overexpression	of	Ang2	caused	a	similar	phenotype	as	that	in	Ang1-null	mice,	suggesting	that	Ang2	acts	as	a	natural	antagonist	for	Ang1	(95).	The	 Ang/Tie	 system	 controls	 sprouting	 angiogenesis,	 vascular	 maturation	 and	 the	transition	between	the	quiescent	and	activated	endothelium	(96).	During	 angiogenesis,	 pericytes	 produce	 Ang1,	 which	 binds	 Tie2	 receptors	expressed	 by	 the	 stalk	 and	 phalanx	 to	mediate	 vascular	 stabilization.	 The	 Ang1/Tie2	complex	maximizes	the	interaction	between	ECs	and	pericytes	through	the	establishment	of	adherents	and	tight	junctions	in	order	to	reduce	EC	permeability	(Fig.	8).	Moreover,	
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Ang1/Tie2	signaling	induces	the	expression	of	heparin-binding	epidermal	growth	factor-like	growth	factor	(HB-EGF),	which	stimulates	mural	migration	though	epidermal	growth	factor	receptors	(EGFRs)	(97).	In	contrast,	during	active	angiogenesis,	Ang2	released	from	Weibel-Palade	bodies	acts	as	a	destabilizing	 factor	 in	an	 autocrine	way.	Ang2	competes	with	Ang1	 for	Tie2	binding	and	does	not	induce	signal	transduction.	This	competition	results	in	a	reduction	in	pericyte	coverage	and	an	increase	in	permeability	and	tip	cells	begin	to	spout	(Fig.	8).	Recent	studies	have	also	demonstrated	that	pericytes	express	Tie2	receptors.	Therefore,	Ang1	 expressed	 by	 pericytes	 acts	 autocrine	 on	 pericytes	 and	 contributes	 to	 vascular	maturation.	On	the	other	hand,	Ang2	released	by	endothelial	cells	binds	Tie2	pericytes	and	favors	vessel	destabilization	directly	on	pericytes	(98).										
	
Figure	8.	Vascular	effect	of	the	Ang-Tie	system.	Quiescent	endothelium	is	covered	by	pericytes	that	secrete	Ang1.	Ang1/Tie2	 interaction	 causes	 receptor	 clustering	 and	 activation	 of	 survival	 signal	 pathways	 (PI3K/Akt),	 thus	promoting	EC	survival	and	stabilization.	Ang2	is	stored	and	rapidly	released	from	WPBs	by	activated	endothelial	cells.	Ang2	acts	as	an	autocrine	binding	Tie2	and	competing	with	Ang1.	As	a	consequence,	vessels	are	destabilized,	pericytes	detach	and	endothelial	cells	start	to	sprout	(Adapted	from	Van	Meurs	M.	et	al.,	2009).	
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2.1.4	 S1P1/EDG1	signaling	Sphingosine-1-phosphate	 (S1P1)	 is	 a	 lipid	mediator	which	has	 emerged	 as	 important	molecule	in	the	regulation	of	vascular	formation	and	maturation	(99).	S1P1	is	generated	after	 sphingosine	 phosphorylation	 by	 sphingosine	 kinases	 (SphKs)	 (100).	 S1P1	 is	secreted	by	cells	and	transported	extracellulary	on	lipoprotein	particles.	It	interacts	with	G-protein-coupled	 receptors	 (denoted	 as	 S1P1	 to	 5)	 to	 trigger	 multiple	 downstream	signaling	processes	(101).	S1P1	(edg1)-null	mice	died	in	utero	at	E12.5	due	to	vascular	abnormalities	 caused	 by	 the	 defective	 migration	 of	 pericytes.	 S1P1	 regulates	 vessel	formation	 positively	 and	 negatively	 by	 the	 activation	 of	 specific	 receptor	 subtypes.	Moreover,	double	or	triple	knockout	of	S1P1–3	caused	more	severe	vascular	defects	and	earlier	 lethality	(Spiegel	S.,	2003).	 In	vitro,	S1P1	stimulates	cytoskeletal,	adhesive,	and	junctional	 changes,	 favoring	 cell	 migration,	 proliferation	 and	 survival	 (102).	 S1P	 is	secreted	by	monocytes	and	activated	platelets;	S1P	binding	to	EDG1	on	endothelial	cells	improves	ECM	production.	Moreover,	the	activation	of	S1P1	on	pericytes	enhances	their	migration	 towards	 endothelial	 cells	 (68).	 EDG1	 signaling	 might	 promote	 vessel	stabilization	through	N-cadherin–based	endothelial–pericyte	contacts	(103).	In	contrast,	S1P2	(EDG5)	negatively	regulates	angiogenesis	activity	as	it	reduces	mural	cell	migration	through	Rac	inhibition	(104).			
2.1.5	 TGF-β	signaling	in	angiogenesis	
2.1.5.1	TGF-β	family	and	receptors	The	transforming	growth	factor	beta	(TGF-β)	superfamily	is	an	evolutionarily-conserved	family	of	secreted	factors	which	is	comprised	of	thirty-three	members,	including	TGF-β	isoforms,	activins,	anti-Müllerian	hormone	(AMH),	bone	morphogenetic	proteins	(BMPs)	
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and	 growth	 and	 differentiation	 factors	 (GDFs)	 (105).	 TGF-β	 family	 members	 play	 a	critical	role	during	embryogenesis	and	 in	maintaining	tissue	homeostasis	 in	adult	 life.	Dysregulation	 in	 TGF-β	 signaling	 pathway	 is	 associated	 with	 several	 developmental	disorders	 and	 diseases	 comprising	 cancers,	 autoimmune	 diseases,	 fibrosis	 and	cardiovascular	diseases	(106).	There	are	TGF-β	isoforms	(TGF-β1,	TGF-β2	and	TGF-β3)	and	human	isoforms	are	encoded	by	genes	located	in	different	chromosomes:	19q13.1,	1q41	and	14q24,	respectively	(107).	TGF-β	isoforms	can	act	in	autocrine,	paracrine	and	endocrine	ways	to	regulate	different	processes.	The	availability	of	their	active	forms	is	tightly	 controlled	 at	 multiple	 levels,	 including	 secretion	 and	 interaction	 with	 ECM	components	(108).	In	fact,	polypeptides	from	TGF-β	family	are	synthetized	as	secreted	inactive	 latent	 dimeric	 precursors	 (pre-pro-TGFs)	 composed	 of	 a	 monomer	 with	molecular	weight	of	55kD,	N-terminal	signal	peptides	(SP),	a	pro-region	named	latency-associated	peptide	(LAP),	and	C-terminal,	which	corresponds	to	the	functionally-active	cytokine	(109).	The	association	of	the	monomer	and	LAP	form	the	small	latent	complex	(SLC).	SLC	subsequently	interacts	covalently	with	the	large	latent	TGF-β	binding	protein	(LTBP)	to	form	a	larger	complex	called	larger	latent	complex	(LLC).	After	secretion,	the	LLC	anchors	the	ECM	and	it	is	maintained	in	an	inactive	form	(110).	TGF-β	is	activated	by	different	 mechanisms,	 including	 proteolytic	 cleavage	 of	 LAP	 and	 LTBP	 by	thrombospondin-1,	 plasmin,	 pH	 alteration,	 matrix	 metalloproteinase	 (MMP)	 and	 by	integrin	 interaction.	The	 last	mechanism	is	unclear;	however,	 the	 interaction	between	integrin	and	the	RGD	domains	in	LAP	might	induce	conformational	changes	that	result	in	the	liberation	of	the	mature	protein	(111).		Once	 the	 active	 form	 of	 the	 TGF-β	 member	 is	 released	 from	 the	 extracellular	matrix,	 it	can	signal	 trough	a	complex	of	 type	 I	 (TβRI,	 also	known	as	Activin	receptor	ALK5)	 and	 type	 II	 (TβRII)	 serine/tyrosine	 kinase	 receptors.	 TGF-β	 receptors	 are	
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transmembrane	glycoproteins,	which	are	expressed	on	the	surface	of	endothelial	cells,	mural	 cells	 and	 several	 other	 cell-type.	 Ligand	 binding	 induces	 heterotetrameric	assembly	 of	 type	 I	 and	 type	 II	 receptors	 (112).	 In	 humans,	 there	 are	 seven	 type	 I	receptors:	the	Alk5	group	that	includes	Alk5,	Alk4	and	the	Nodal	receptor	Alk7;	the	Alk3	group	composed	of	the	BMP	type	I	receptors	Alk3	and	Alk6;	and	the	Alk1	group	(Alk1	and	Alk2).	 The	 five	 type	 II	 receptors	 are	 TβRII,	 Activin	 and	 BMP/GDF	 type	 II	 receptors,	BMP/GDF	type	II	receptors	(BMP	RII)	and	Mullerian	inhibitory	substance	(MIS)	type	II	receptors	(113).	 It	 is	possible	 to	distinguish	three	main	receptor	domains,	 including	a	small	 cysteine-rich	 extracellular	 domain,	 a	 transmembrane	 domain	 and	 a	 C-terminal	intracellular	 portion	 containing	 the	 binding	 site	 for	 serine/threonine	 protein	 kinase	(112,	114).	Upon	type	I	receptor	activation,	intracellular	signals	are	propagated	through	‘canonical’	effector	proteins	of	the	Smad	Family.	Receptor-regulated	Smads	(R-Smad)	are	then	phosphorylated	at	two	serine	residues	at	the	C-terminus	allowing	the	formation	of	a	complex	with	the	common	mediator	Smad4.	Subsequently,	the	complexes	translocate	into	the	nucleolus	to	regulate	the	expression	of	specific	genes	such	as	SERPINE1	(also	known	as	PAI-I,	plasminogen	activator	inhibitor)	and	ID1	(inhibitor	of	DNA	binding-1)	in	cooperation	with	other	transcriptional	factors	(109,	115).	ALK4,	5	and	7	mediate	the	phosphorylation	of	R-Smad	2	and	3,	whereas	ALK	1,	2,	3	and	6	induce	phosphorylation	of	R-Smad	1,	5	and	8	(106).	TGF-β	can	also	signal	through	a	non-canonical	pathway	(Smad-independent	 pathway)	 via	 other	 intracellular	 signals,	 which	 may	 include	 mitogen-activated	 proteins	 (MAPK),	 extracellular-signal-regulated	 kinases	 1/2	 (ERK1/2)	 and	PI3K,	among	others	(114).	
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2.1.5.2	TGF-β/TβR	signaling	in	EC	and	mural	cells	TGF-β	is	an	important	cytokine	expressed	by	endothelial	cells	and	pericytes	during	vessel	formation.	 TGF-β	 signaling	 regulates	 angiogenesis	 by	 different	 mechanisms,	 and	 is	implicated	 in	 mural	 cell	 and	 EC	 differentiation	 and	 proliferation	 (67).	 In	 vivo	 loss	 of	function	of	TGF-β	signaling	members	resulted	in	an	abnormal	primitive	capillary	plexus	
Figure	9.	TGF-β	canonical	pathways.	Canonical	signal	transduction	by	TGF-β	family	members	can	be	divided	into	two	main	pathways	based	on	the	R-Smad	effector	involved.	TGF-β	ligands	can	bind	to	type	I	or	type	II	receptors,	specifically	TGF-β	signals	via	TGFBR2	and	ALK5	and	BMPs	signals	via	the	BMP	type	II	receptor	(BMPR2)	and	ALK1,	-2,	-3	and	-6.	Accessory	receptors	like	betaglycan	and	endoglin	can	modulate	receptor	signaling.	Receptor	activation	induces	the	phosphorylation	of	the	intracellular	effector	R-Smads.	Normally,	TGFβ	induces	Smad2/3	phosphorylation	and	BMPs	induce	Smad1/5/8	phosphorylation.	Phosphorylated	Smads	form	complexes	and	translocate	into	the	nucleus	where,	in	cooperation	with	other	transcription	factors,	they	regulate	gene	expression	responses.	Inhibitory	Smads	(I-Smads)	antagonize	TGF-β	signaling	by	inhibiting	the	activation	of	R-Smads	(Adapted	from	Dijke	P.	et	al.,	2007).	
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with	impaired	recruitment	of	mural	cells.	Embryos	lacking	one	of	the	components	die	at	the	mid-gestation	stage	due	to	hyper-dilated	and	leaky	vessels.	Null	mice	of	endothelial	ALK5	or	TβRII	die	at	E10.5	with	severe	vascular	defects	(116,	117).	It	has	been	proposed	that	TGF-β	regulates	the	activation	state	of	the	endothelium	by	alternating	the	activation	of	two	signaling	cascades	with	opposite	effects	(ALK5	and	ALK1)	(118).	Briefly,	TGF-β	signaling	through	ALK5	induces	phosphorylation	of	Smad2/3,	expression	of	fibronectin	and	plasminogen	activator	inhibitor	type	I	(PAI-1),	leading	to	inhibition	of	EC	migration	and	proliferation.	In	contrast,	TGF-β/ALK1	signaling	induces	the	activation	of	Smad1/5	and	 up-regulation	 of	 Id-1	 to	 promote	 EC	migration,	 proliferation	 and	 tube	 formation	(106).	 ALK1	 can	 interfere	 with	 ALK5/Smad2/3	 pathway	 signaling.	 Therefore,	 the	combined	effects	promote	 the	angiogenic	activation	phase	 characterized	by	 increased	vascular	 permeability,	 basement	 membrane	 degradation	 and	 EC	 proliferation.	 In	 the	second	 phase,	 ALK1-mediated	 pathways	 are	 down-regulated	 and	 ALK5	 signaling	regulates	 the	 resolution	 phase	 of	 angiogenesis,	 in	 which	 ECs	 stop	 to	 proliferate	 and	differentiate	and	the	basal	 lamina	 is	restored	(119).	Moreover,	 it	has	been	shown	that	BMPs	regulate	EC	function	as	well.	BMP6	promotes	EC	migration	via	Smad1/5	activation,	while	BMP4	induces	cell	proliferation	and	migration	through	the	up-regulation	of	VEGF-A	(120).	TGF-β	signaling	also	affects	pericyte	and	SMC	proliferation	and	differentiation.	Specific	 knockout	 of	 TβRII	 vascular	 smooth	 muscle	 cells	 was	 lethal	 at	 E12-5	 due	 to	vascular	 defects	 in	 the	 yolk	 sac	 (117).	 Carvalho	 et	 al.	 have	 showed	 that	 endoglin	knockouts	and	endothelium-specific	knockouts	of	tβrII	and	alk5	cause	the	loss	of	TGF-β	signaling	in	the	endothelium,	which	impairs	TGF-β/ALK5	signaling	in	mesenchymal	cells	as	well,	consequently	inhibiting	their	differentiation	into	VSMC	and	their	association	with	the	 vessels.	 Furthermore,	 ALK1	 activation	 stimulates	 pericyte	 recruitment	 to	 new	
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vasculatures	while	 ALK	 5	 signaling	 promotes	 cell	 quiescence	 and	 vessel	 stabilization	(68).	
2.1.6	 Ephrins	and	Eph	receptors	signaling	The	erythropoietin-producing	hepatocellular	(Eph)	receptor	family	is	the	largest	class	of	tyrosine	kinase	receptors	in	mammals.	Ephs	have	an	extracellular	domain	consisting	of	a	highly-conserved	N-terminal	ligand-binding	domain,	a	cysteine-rich	region	composed	of	an	epidermal	growth	factor	(EGF)-like	domain,	and	two	fibronectin	type	III	motifs	(FN	III)	(121).	The	intracellular	domain	contains	tyrosine	kinases,	sterile-α	motifs	(SAM)	and	PDZ-binding	motif	which	promote	oligomerization	of	 the	 receptors	 (Fig.	10)	 (122).	 In	humans,	 there	 are	 nine	 EphA	 receptors	which	 are	 attached	 to	 the	 cell	 surface	with	 a	glycosylphosphatidynositol	(GPI)	and	five	Eph	type	B	receptors,	which	are	characterized	by	a	shot	cytoplasmic	region.	The	ligands	are	also	categorized	into	classes	A	and	B	and	into	five	subclass-A	ephrin	ligands	and	five	ephrin-B	ligands	(123).	Eph	type	B	receptors	bind	ephrin	ligands	and	form	the	subclass	B	type,	while	Eph-A	interacts	with	ephrin	type	A,	with	some	exceptions.	Eph	receptors	and	ephrin	ligands	are	both	able	to	transduce	a	signaling	cascade	upon	interaction.	Eph-activated	signaling	is	called	forward,	and	ephrin-activated	signaling	is	called	reverse	(Fig.	10).	Another	level	of	complexity	of	Eph/ephrin	signaling	 is	 the	 fact	 that	 interactions	 between	 Ephs	 and	 ephrins	 can	 occur	
in	trans	(between	 two	 opposing	 cells)	 or	 in	cis	(within	 the	 same	 cell).	 Generally,	 it	 is	assumed	that	trans	interactions	are	activating	while	cis	interactions	are	inhibiting	(124).	Eph	and	ephrin	interactions	cause	sequential	clustering	of	the	receptor	ligand/receptor	complex	to	form	high-affinity	heteroteramer	complexes	(121,	125).	
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	 Eph	 receptors	 and	 their	 ephrin	 ligands	 control	 several	 cell-cell	 interactions,	including	those	of	vascular	endothelial	cells	and	epithelial	and	stem	cells.	They	also	have	vital	 roles	 in	 bone	 mineral	 metabolism	 and	 the	 immune	 system.	 Veins	 and	 arteries	differentially	 express	 the	members	 of	 the	 Eph	 family.	 EphrinB2	 is	 an	 arterial	marker	while	EphB4	is	expressed	in	veins	(126).	EphB4	and	ephrinB2	are	crucial	 for	vascular	remodeling	of	primitive	capillary	networks	into	distinct	arteries	and	veins.	Mutations	of	ephrinB2	and	EphB4	are	caused	embryonic	lethality,	suggesting	that	both	molecules	are	essential	 during	 the	 remodeling	 of	 the	 primary	 vascular	 plexus	 (127).	 Moreover,	endothelial-specific	knockout	of	Efnb2	cause	embryo	death	due	to	a	complete	arrest	of	angiogenesis	(128).	However,	pericytes	and	vascular	smooth	muscle	cells	also	express	ephrinb2.	Deletion	of	ephrinB2	in	pericytes	and	in	smooth	muscle	cells	resulted	in	diffuse	tissue	 edema,	 hemorrhaging	 and	 perinatal	 death	 of	 the	 mice	 (129).	Furthermore,	activation	of	EphB4	in	mural	cells	reduced	their	ability	to	migrate,	suggesting	that	EphB4	signaling	 in	 pericytes	 may	 favor	 their	 attachment	 to	 the	 endothelial	 cells,	 therefore	stabilizing	the	vessel	wall	(130).	
Figure	 10.	 Schematic	 representation	 of	 Eph	 receptor	 and	 ephrin	 ligand	 structures	 and	 bindings.	 (A)	 Eph	receptors	are	membrane-bound	proteins	consisting	of	a	cysteine-rich	region,	FN	type	III	motifs,	a	 juxatamembrane,	tyrosine	kinase	domain	and	SAM	and	PDZ	binding	sites.	The	ephrin-B	ligands	are	transmembrane	proteins,	whereas	ephrin	from	the	subclass	A	are	linked	to	the	membrane	via	a	GPI	anchor.	(B)	Eph/ephrin	pathways	can	signal	forward	through	cells,	expressing	the	receptor	or	reverse	through	ephrin-expressing	cells	(Adapted	from	Salvucci	O.	et	al,	2012).		
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2.2 Role	of	Sema3A	in	Angiogenesis	and	Stabilization	Semaphorins	are	a	family	of	secreted	and	transmembrane	proteins,	originally	identified	as	 axonal	 guidance	modulators,	 which	 have	 been	 shown	 to	 signal	 through	 two	main	receptor	 families:	plexins	and	Neuropilins	(NPs)	(131).	Semaphorins	are	grouped	 into	eight	major	classes	on	the	basis	of	their	sequence	and	overall	structure	characteristics.	Furthermore,	all	 the	members	of	 this	 family	have	a	conserved	extracellular	domain	of	500	amino	acids	known	as	the	semaphorin	domain,	which	is	a	key	component	through	which	semaphorins	mediate	their	effects	(Fig.	11)	(132).	Class-1	and	class-2	semaphorins	are	found	in	invertebrates,	while	classes	3	to	7	are	present	only	in	vertebrates.	Moreover,	classes	1,	4,	5	and	6	are	membrane-bound	proteins,	while	classes	2	and	3	are	 instead	secreted.	 Class-7	 semaphorins	 are	 glycosylphosphatidylinositol	 (GPI)-linked	 proteins	(133).	 This	 family	 of	 proteins	 is	 predominantly	 expressed	 during	development	 in	 the	nervous	system;	however,	they	are	also	expressed	in	several	tissue	and	organ	systems	including	 the	 cardiovascular,	 endocrine,	 gastrointestinal,	 hepatic,	 immune,	musculoskeletal,	renal,	reproductive	and	respiratory	systems	(132,	134).	In	particular,	class-3	semaphorins	(Sema3)	have	been	shown	to	play	a	crucial	role	in	cardiovascular	development	and	vascular	maturation.			
2.2.1 Semaphorins	class-3	Family	In	 mammals,	 class-3	 semaphorins	 consist	 of	 7	 soluble	 proteins	 of	 about	 100	 kDa—namely	Sema3A,	Sema3B,	Sema3C,	 Sema3D,	Sema3E,	 Sema3F	and	Sema3G,	which	are	secreted	by	several	cells	 including	endothelial	cells,	epithelial	cells,	neurons	and	some	tumor	cells	(135).	Sema3s	comprise	a	conserved	sema	domain,	a	plexin-semaphorins-integrin	(PSI)	domain,	an	Ig-like	motif	and	a	C-terminal	basic	domain.	Semaphorins	are	
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functionally	 active	 as	 dimers;	 the	 sema	 domain,	 the	 Ig	 domain	 and	 the	 formation	 of	disulfide	bridges	at	the	basic	tail	are	essential	for	protein	dimerization.	Moreover,	the	C-terminal	pro-peptide	undergoes	proteolytic	cleavage	by	furine-like	proteases	in	order	to	stabilize	 the	dimers	(136,	137).	Apart	 from	Sema3E,	class-3	semaphorins	 	require	the	formation	of	holoreceptor	complexes	(which	comprise	plexin	and	neuropilin	proteins)	to	exert	 the	 majority	 of	 their	 effects	 (Fig.	 11).	 Neuropilins	 mediate	 Sema3	 signaling	 in	collaboration	with	signal	transduction	receptors,	like	plexins	and	cell	adhesion	molecules	(CAMS)	(138).											
	 Plexins	are	a	family	of	transmembrane	molecules	divided	into	four	classes,	A	to	D.	The	extracellular	domain	of	plexins	is	a	sema	domain	which	mediates	binding	with	Sema3	dimers	(Fig.	11).	The	intracellular	region	contains	a	guanosine	triphodphstase	(GTPase)-
Figure	11.	Class-3	semaphorins	and	their	receptors.	(A)	Sema3s	are	a	large	family	of	soluble	and	transmembrane	proteins	characterized	by	a	conserved	sema	domain	and	a	PSI	motif.	Classes	4,	5	and	6	are	membrane-bound	proteins,	while	class	7	is	anchored	to	the	membrane	via	GPI.	Of	the	vertebrate	semaphorins,	class-3	semaphorins	are	secreted	proteins	that	have	a	basic	C-terminal	which	is	crucial	 for	the	binding	with	neuropilin	receptors.	Some	semaphorins	contain	 Ig-like	motifs.	 (B)	Neuropilins	are	transmembrane	 receptors	which	are	 comprised	of	 two	complement-like	(CUB)	domains	(a1/a2	domains),	two	factor	FV/FVIII	coagulation	factor-like	domains	(b1/b2	domains)	and	a	MAM	domain	 (also	 called	 the	 c	 domain).	 (C)	 Plexins	are	 transmembrane	molecules	 consisting	 of	 one	 sema	 domain,	 PSI	domains	and	Ig-like	domains.	The	cytoplasmic	domain	of	plexins	is	composed	of	two	GTPase-activating	proteins	(GAP)	(Adapted	from	Capparuccia	L.	et	al,	2009).		
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activating	 protein	 (GAP)	 homology	 domain.	 Sema3/NRP/plexin	 signal	 transduction	 is	still	 poorly	 understood.	 Actually,	 the	 best-described	 semaphorin	 signal	 cascades	 are	those	used	for	axon	guidance	(132).	There	is	a	growing	consensus	that	several	class-3	semaphorins,	such	as	Sema3A	and	Sema3E,	are	involved	in	physiological	and	pathological	angiogenesis.		
2.2.2 Role	of	Sema3A	in	angiogenesis	Semaphorin	 3A	was	 first	 described	 as	 an	 axon	 guidance	 factor	which	 signals	 via	 the	holoreceptor	complex	that	contains	neuropilin	1	(NP1)	as	the	ligand-binding	subunit,	and	A-Plexin	that	represents	the	signal-transducing	subunit	(139).	Sema3A	specifically	binds	to	NP1	and	not	to	NP2	(140).	NP1	is	also	known	as	VEGF	co-receptor.	Therefore,	it	was	assumed	 that	 Sema3A	 could	 interfere	with	 NP1-mediated	 VEGF	 signaling	 and	 inhibit	VEGF	 binding	 to	NP1.	However,	 it	was	 demonstrated	 that	 Sema3A	 and	VEGF	binding	domains	 on	 NP1	 are	 completely	 different	 (141,	 142).	 The	 role	 of	 Sema3A	 during	angiogenesis	appears	to	be	controversial.	Sema3A	knockout	mice	in	a	CD-1	background	showed	 a	 reduction	 in	 vascular	 remodeling	 when	 compared	 with	 wild-type	 animals	(143).	However,	these	results	have	not	been	reproduced	in	another	study	with	Sema3A-null	 CD-1	mice,	 presumably	 because	 of	 mutant	 variation	 depending	 on	 mice	 genetic	background	 (144).	 Nevertheless,	 Sema3A	 deletion	 in	 another	 mice	 strain	 resulted	 in	severe	 renal	 vascular	 defects,	 supporting	 the	 importance	 of	 Sema3a	 in	 angiogenic	remodeling.	Sema3A	treatment	in	vitro	caused	a	significant	inhibition	in	endothelial	cell	migration	(145).			 Maione	et	al.	have	demonstrated	that	Sema3A	acts	as	an	endogenous	inhibitor	of	angiogenesis	in	premalignant	lesions	and	is	down-regulated	during	tumor	progression.	
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Sema3A	 restored	 with	 an	 adeno-associated	 virus	 resulted	 in	 a	 decrease	 in	 tumor	angiogenesis	 and	 tumor	 growth.	 Significantly,	 long-term	 expression	 of	 Sema3A	 in	 the	tumor	 model	 strongly	 improved	 pericyte	 coverage	 of	 tumor-induced	 blood	 vessels,	therefore	 normalizing	 tumor-induced	 angiogenesis.	 They	 observed	 that	 Sema3A	expression	 is	 an	 inhibitor	 of	 tumor	 angiogenesis;	 however,	 it	 can	 favor	 vascular	stabilization	by	increasing	pericyte	recruitment	(146).	Nevertheless,	the	mechanisms	of	Sema3A-mediated	perivascular	cell	recruitment	to	tumor	vessels	remains	to	be	elucidate.	Recently,	it	has	been	shown	that	Sema3A/NP1	signaling	influences	arterial	formation	and	lymphatic	vessel	maturation	via	regulating	pericyte/smooth	muscle	cell	coverage	(147,	148).		
2.2.3 Role	of	accessory	cells	in	the	formation	of	blood	vessels	Bone	marrow	(BM)-derived	cells	have	been	credited	with	promoting	vessel	sprouting	and	stabilization	of	newly-induced	vascular	 structures.	During	postnatal	 angiogenesis,	BM-derived	 hematopoietic	 cells	 can	 differentiate	 in	 endothelial	 cells	 and	mural	 cells,	contributing	to	neovessel	formation	(149).	Many	reports	have	shown	that	hematopietic	precursors	 are	 mobilized	 into	 the	 avascular	 area	 and	 maintained	 in	 a	 perivascular	position	where	 they	promote	 sprouting	angiogenesis	by	producing	angiogenic	 signals	such	as	VEGF	and	angiopoietins	to	chemoattract	EC	(150).		 During	 adult	 neovascularization,	 VEGF	 signaling	 promotes	 the	 income	 of	 a	population	of	bone	marrow-derived	CXC	chemokine	receptor	4	(CXCR4)-expressing	cells.	The	stromal	derived-factor-1	(SFD-1)	produced	by	perivascular	cells	in	response	to	VEGF	favor	 CXCR4+	 cell	 retention	 within	 the	 tissues.	 These	 bone	 marrow-circulating	 cells	enhance	in	situ	endothelial	cell	proliferation	during	vessel	formation.	CXCR4	inhibition	
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and	the	resultant	failure	to	retain	CXCR4+	cells	leads	to	inhibition	of	angiogenesis	(151,	152).		 Moreover,	 Zacchigna	 et	 al.	 have	 demonstrated	 the	 presence	 of	 a	 population	 of	bone	 marrow-derived	 cells	 recruited	 by	 NP1	 receptors	 at	 the	 site	 of	 VEGF-induced	angiogenesis.	These	infiltrating	cells	are	CD11b+	and	they	express	the	VEGF	and	Sema3a	co-receptor	NP1.	They	are	therefore	named	NP1-expressing	mononuclear	(NEM)	cells.	NEM	are	not	arteriogenic	and	they	are	not	incorporated	in	the	newly-formed	vasculature.	However,	 they	 favor	 arterial	maturation	 through	 the	 secretion	 of	 different	 paracrine	factors—notably	 Ang1,	 TGFβ	 and	 PBGF-BB.	 Their	 paracrine	 effect	 results	 in	 the	activation	and	proliferation	of	smooth	muscle	cells	and	pericytes	(147).	Among	myeloid	cells,	Tie2-expressing	monocytes	(TEMs),	which	represent	2%	of	circulating	monocytes,	play	a	crucial	role	during	tumor	angiogenesis.	TEMs	are	recruited	in	the	tumor	through	Ang2,	where	they	secrete	paracrine	 factors	such	as	VEGF,	MMP9,	COX2	and	Wnt5A	to	promote	tumor	angiogenesis.	Depletion	of	TEMs	impairs	tumor	growth	and	angiogenesis	(153).		
2.2.4 Vascular	stabilization	through	the	Sema3A/NEM	Axis	Recently,	we	revealed	the	presence	of	an	endothelial	paracrine	axis	 involving	Sema3a,	NP1-expressing	 monocytes	 and	 TGF-b1	 which	 favors	 vascular	 maturation	 and	stabilization	 (154).	During	VEGF-induced	 angiogenesis	 in	 skeletal	muscles,	 increasing	doses	of	VEGF	have	a	negative	impact	on	vessel	stabilization.	Vascular	stabilization	was	defined	 as	 the	 portion	 of	 newly-induced	 vessels	 independent	 from	 further	 VEGF	signaling.	Withdrawal	of	VEGF	by	Aflibercept	treatment	at	two	and	three	weeks	resulted	in	 the	 regression	of	 the	vessel	 induced	by	high	 levels	of	VEGF.	However,	 the	vascular	
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network	induced	by	low-VEGF	doses	was	partially	stabilized	where	around	50%	of	the	vessels	were	independent	from	VEGF	stimulus	at	three	weeks.	The	differences	in	vascular	stabilization	did	not	correlate	with	changes	in	pericyte	coverage.	Significantly,	some	pro-maturation	factors	such	as	TGF-b1	and	Sema3A	were	dose-dependently	down-regulated	by	increasing	levels	of	VEGF	(154).	VEGF	and	Sema3a	can	recruit	NEM,	which	promotes	mural	 cell	 recruitment	 during	 arteriogenesis	 (147).	 The	 impairment	 in	 Sema3A	expression	 in	 the	 presence	 of	 high	 doses	 of	 VEGF	 correlated	with	 a	 decrease	 in	NEM	recruitment	while	at	low	doses,	the	number	of	NEM	increased	when	compared	to	control	conditions	 matching	 the	 stabilization	 profile.	 NEM	 recruited	 by	 low	 levels	 of	 VEGF	expressed	 paracrine	 factors	 known	 to	 favor	 vascular	 maturation	 such	 as	 TGF-b1.	Moreover,	 TGF-b1	 dose-dependent	 down-regulation	 prevented	 the	 activation	 of	 a	Smad2/3	pathway	known	 to	mediate	endothelial	quiescence	and	vascular	maturation	(106).										
	
Figure	12.	Sema3A/TGF-b1/NEM	axis.	Low	doses	of	VEGF	cause	up-regulation	of	endothelial	Sema3A,	which	recruits	NEM	in	the	area	of	active	angiogenesis.	Subsequently,	NEM	produces	TGF-b1	which,	on	one	hand,	activates	Smad2/3	pathways	favoring	vessel	stabilization	and,	on	the	other,	hand-stimulates	additional	Sema3A	expression	by	endothelial	cells.	At	a	high	level	of	VEGF,	Sema3A	is	down-regulated	in	endothelial	cells,	causing	an	impairment	in	NEM	recruitment	and	TGF-b1	release	and	resulting	in	a	delay	in	vascular	stabilization	(Adapted	from	Groppa	E.	et	al,	2015).	
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Additionally,	we	found	that	TGF-b1	induced	Sema3a	expression	whereas	VEGF	inhibited	it	and	TGF-b1	abrogation	resulted	in	a	down-regulation	of	Sema3A	and	reduction	in	NEM	recruitment.	Finally,	Sema3A	treatment	favors	vessel	stabilization	of	vessels	induced	by	high	 VEGF	 doses	 without	 inhibiting	 angiogenesis.	 These	 findings	 demonstrate	 the	presence	of	a	novel	feedback	loop	where	TGF-b1	secreted	by	Sema3A-recruited	NEM	up-regulates	 endothelial	 Sema3A	 and	 induces	 endothelial	 cell	 quiescence,	 promoting	vascular	stabilization	(Fig.	12)	(154).																			
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III. Therapeutic	angiogenesis	
Therapeutic	angiogenesis	aims	to	stimulate	the	formation	of	new	blood	vessels	from	a	preexisting	vasculature	 to	 treat	 ischemic	diseases.	Delivery	of	 angiogenic	 factor	using	genes,	 proteins	 and	 cells	 have	 shown	 a	 certain	 efficiency	 in	 animal	models.	However,	clinical	angiogenesis	trials	have	proved	challenging	for	demonstrating	positive	results	in	patients	 (155).	 Various	 reasons	 have	 been	 considered	 for	 the	 failure	 of	 clinical	 trials,	ranging	 from	poor	gene	transfer	technology	to	short	duration	of	 transgene	expression	and	a	 lack	 in	persistency	of	vessels	 induced	by	therapy	(156).	 Ischemic	diseases	are	a	group	of	cardiovascular	diseases	caused	by	a	decrease	in	oxygen	supply	to	the	tissues.	These	 diseases	 can	 occur	 in	 the	 heart	 (coronary	 heart	 disease),	 in	 the	 brain	(cerebrovascular	disease)	and	in	the	peripheral	limbs	(peripheral	artery	disease)	(157).	Ischemic	disease	represents	one	of	the	main	heath	care	issues	worldwide	that	continues	to	be	the	leading	cause	of	morbidity	and	mortality	(158).		
3.1 Peripheral	artery	disease	Peripheral	artery	disease	(PAD)	is	a	common	circulatory	problem	characterized	by	the	narrowing	of	peripheral	arteries	due	to	the	formation	of	atherosclerotic	plaques	and	the	subsequent	 decrease	 in	 blood	 supply	 (159).	 Atherosclerosis	 is	 the	 principal	pathophysiological	process	 leading	 to	PAD.	The	pathological	phases	of	 atherosclerosis	can	be	divided	into	three	main	stages:	I)	lesion	initiation	due	to	endothelial	dysfunction	by	 hypertension,	 hyperlipidemia,	 inflammation	 or	 oxidative	 stress;	 II)	 fatty	 streak	formation	and	accumulation	in	the	artery	wall—a	stage	defined	by	the	accumulation	of	lipoproteins	 and	 by	 smooth	 muscle	 cell,	 monocyte,	 macrophage	 and	 lymphocyte	recruitment;	 and	 III)	 lesion	 maturation,	 where	 the	 lesion	 becomes	 a	 fibrotic	 plaque	
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composed	of	a	growing	mass	of	lipids	(mainly	cholesterol)	and	connective	tissue.	With	the	progression	of	the	disease,	the	fibrotic	plaques	accumulate	and	grow,	causing	stenosis	of	 the	artery	or	complete	occlusion.	Eventually,	rupture	of	atherosclerotic	plaques	can	result	in	myocardial	infarction	and	stroke	or	acute	leg	ischemia	(160).	Peripheral	artery	disease	affects	more	the	13%	of	 the	population	of	Western	countries,	usually	 in	 those	who	are	more	than	50	years	old.	The	major	risk	factors	associated	with	PAD	are	smoking,	diabetes,	 advancing	age,	hypertension	and	dyslipidemia.	Most	patients	with	PAD	have	mild	or	no	symptoms;	however,	some	people	experience	aching	or	burning	muscles	when	walking	 (claudication).	PAD	can	progress	to	a	more	severe	 form	over	 time,	 leading	 to	resting	pain	and	even	tissue	loss	(critical	limb	ischemia)	(161).	The	current	treatments	for	PAD	include	the	reduction	of	risk	factors	including	tobacco	cessation,	the	adoption	of	a	healthy	diet	and	exercise	and	antiplatelet	medication	therapy.	Moreover,	patients	can	undergo	 invasive	 revascularization	 procedures	 such	 as	 angioplasty,	 artery	 bypass	grafting	 and	 stenting.	 Despite	 advances	 in	 these	 treatments,	 however,	 up	 to	 30%	 of	patients	 with	 PAD	 cannot	 be	 treated	 due	 to	 peri-operative	 risk	 factors	 or	 patient	comorbidities.	 In	 addition,	 some	patients	 can	 develop	 restenosis	 following	 treatment,	resulting	 in	a	diminished	quality	of	 life.	Therefore,	 there	 is	 currently	a	push	 for	novel	therapeutic	 alternatives	 to	 improve	 arteriogenesis	 (collateral	 formation)	 and/or	angiogenesis	(capillary	formation)	in	affected	patients	(157).		
3.2 Angiogenic	therapies	Therapeutic	angiogenesis	is	a	promising	strategy	for	stimulating	blood	vessel	growth	in	the	 ischemic	 tissue	 of	 patients	 who	 are	 not	 good	 candidates	 for	 standard	revascularization	 procedures	 (162).	 An	 increase	 in	 blood	 supply	 and	 shear	 stress	 by	
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newly-induced	vessels	can	trigger	the	opening	of	collateral	arteries	(arteriogenesis)	to	reestablish	 tissue	 function	 and	 encourage	 recovery	 (163).	During	 arteriogenesis,	 pre-existing	 arterioles	 undergo	 processes	 of	 enlargement	 and	 remodeling	 into	 larger,	functional	vessels	to	bypass	arterial	occlusion	(157).	Neo-vascularization	can	be	achieved	by	 exogenous	 administration	 of	 several	 proangiogenic	molecules	 including	 fibroblast	growth	factor	(FGF),	VEGF,	hepatocyte	growth	factor	(HGF),	insulin	growth	factor	(IGF)	and	HIF-1a.	There	are	three	main	strategies	for	therapeutic	angiogenesis:	gene	therapies,	and	protein	and	cell	delivery.	Protein	therapies	are	accomplished	by	simple	injection	of	recombinant	proteins	into	the	target	site	to	promote	vascular	growth.	Protein	production	and	purification	techniques	are	well-established	and	lyophilized	proteins	can	be	easily	reconstituted	 prior	 to	 usage.	 However,	 protein	 therapies	 have	 shown	 disappointing	results	in	trials	due	to	the	short	half-life	of	the	proteins	in	tissues	(164).	Cell	therapies	are	based	on	the	concept	that	candidate	cells	might	differentiate	in	blood	vessel-associated	cells	or	mediate	neovascularization	by	paracrine	secretion	of	angiogenic	factors.	Several	progenitor	cells	can	be	delivered,	including	bone	marrow	mononuclear	cells	(BMMNCs),	mesenchymal	stem	cells	(BMMSCs)	and	endothelial	progenitor	cells	(EPCs).	It	has	been	shown	that	intramuscular	bone	marrow	cell	administration	is	safe,	feasible	and	possibly	efficient	in	patients	with	PAD	(165).	However,	in	vivo	cell	viability	is	quite	low.	In	fact,	most	of	the	time,	delivered	cells	fail	to	integrate	into	the	host	organism	after	delivery.	The	delivery	of	autologous	cells	is	an	attractive	strategy	for	avoiding	both	limitations	in	cell	sources	 and	 host	 immune	 rejection.	Moreover,	 a	 recent	meta-analysis	of	 randomized,	non-randomized	and	non-controlled	studies	of	autologous	cell	therapies	for	peripheral	artery	disease	showed	that	cell-based	therapies	enhance	limb	perfusion	and	functionality	compared	 with	 control	 treatments.	 However,	 the	 efficacy	 of	 these	 therapies	 on	 all	endpoints	lose	their	significance	in	placebo-controlled	studies	and	in	randomized	trials.	
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Currently,	there	is	no	significant	evidence	to	support	the	efficacy	of	cell-based	delivery	treatments	for	patients	with	PAD	(155,	166).	Gene	therapy	via	non-viral	vector	or	viral	vector	is	widely	used	to	promote	revascularization	in	patients	with	PAD	(164).	Non-viral	gene	 transfer	 includes	 plasmid	 delivered	 by	 cationic	 polymers,	 lipids,	 liposomes,	scaffolds	 or	 even	 necked	 plasmids.	 Nevertheless,	 this	 type	 of	 gene	 delivery	 presents	disadvantages,	including	poor	efficiency	of	vector	delivery	and	low	transgene	expression.	Gene	transfer	via	viral	vectors	such	as	adeno-associated	virus,	lentivirus	and	retrovirus	presents	higher	efficacy,	as	these	vectors	are	integrated	into	the	host	genome	and	thus	result	in	high	protein	expression.	However,	their	use	raises	safety	concerns	with	regard	to	immune	hyper-reactivity	and	cytotoxicity.	Moreover,	viral	gene	integration	can	lead	to	interruption	of	tumor	suppression,	gene	expression	or	activation	of	oncogene,	leading	to	malignant	 cell	 transformation	 (167).	 Conversely,	 adeno-associated	 vectors	 (AAV)	 are	safe	 gene	 therapy	 candidates	 thanks	 to	 their	 low	 immunogenicity	 and	 long-term	transgene	expression.	Pro-angiogenic	factor-based	gene	therapy	has	been	administered	with	both	intra-arterial	and	intramuscular	delivery	routes.	Two	plasmid	trials	with	FGF-1	 and	 VEGF,	 respectively—the	 TALISMAN	 (168)	 and	 Groningen	 (169)	 trail	 studies—failed	 to	 show	 significant	 functional	 improvements,	 although	 both	 trials	 showed	 a	beneficial	 effect	 on	 the	 amputation	 rate	 in	 critical	 ischemia	 patients	 (170).	 A	 recent	systematic	review	of	randomized	controlled	trials	of	gene	therapy	in	PAD	showed	that	local	administration	of	proangiogenic	factors	(VEGF,	FGF,	HGF,	Del-1,	HIF-1alpha)	using	gene	transfer	slightly	 improved	hemodynamic	measurements,	ulceration	recovery	and	residual	pain	in	treated	patients.	The	overall	outcomes	of	the	most	recent	clinical	trials	testing	angiogenic	 factors	have	been	disappointing	when	 it	 comes	 to	demonstrating	a	functional	improvement	in	patients.	In	fact,	improved	exercise	performance	or	decreases	in	 major	 limb	 amputations	 and	 mortality	 were	 not	 observed	 (171,	 172).	 Despite	
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encouraging	results	from	preclinical	studies,	clinical	trials	using	angiogenic	factors	did	not	 demonstrate	 a	 successful	 therapeutic	 efficacy	 in	 patients	 with	 peripheral	 artery	disease.		There	are	many	factors	that	are	likely	responsible	for	these	unsuccessful	results.	First,	 an	 ideal	model	of	peripheral	 artery	disease	 is	not	 currently	available.	There	are	several	differences	between	preclinical	models	and	patients.	Clinical	manifestations	 in	humans	are	heterogeneous	and	patients’	comorbidities	can	influence	the	severity	of	the	disease	 and	 the	 responsiveness	 to	 the	 ischemic	 insult.	 Thus	 far,	 none	 of	 the	 existing	preclinical	models	have	reproduced	chronic	ischemia,	as	normal	reperfusion	comes	by	two	and	three	weeks	in	many	mouse	strains.	Therefore,	angiogenic	therapies	tested	in	preclinical	 animal	models	have	most	 likely	 led	 to	excessively-optimistic	results	which	have	 not	 been	 observed	 in	 patients	 (157,	 164).	 Moreover,	 over-dilated	 non-stable	induced	vessels	and	low	and	short-time	transgene	expression	are	also	possible	reasons	for	potential	 failure	of	clinical	 trials.	Patient	selection	may	affect	 the	results	of	clinical	trials.	 Presumably,	 only	 a	 subgroup	 of	 PAD	 patients	 might	 benefit	 from	 therapeutic	vascular	growth.	Others	with	critical	limb	ischemia	actually	cannot	be	revascularized,	as	a	significant	number	of	new	vessels	and	collateral	arteries	would	be	expected	to	see	a	proper	 improvement	 in	 these	 patients.	 Consequently,	 future	 clinical	 trials	 should	necessarily	identify	patient	subgroups	which	can	respond	positively	to	treatments	and	develop	new	biomarkers	to	drastically	improve	therapeutic	angiogenic	treatments	(170).		
3.3 Limitation	in	VEGF	delivery:	dose	and	duration	The	 most	 promising	 candidate	 for	 proangiogenic	 therapeutic	 studies	 is	 vascular	endothelial	growth	factor	A,	known	as	the	master	regulator	of	angiogenesis.	Most	VEGF-
Introduction	
	
	
	 50	
based	clinical	trials	have	been	unsuccessful	in	show	functional	benefit	in	PAD	patients.	VEGF	 gene	 delivery	 studies	have	 demonstrated	 the	 presence	 of	 a	 narrow	 therapeutic	window	in	vivo.	While	low	doses	of	VEGF	are	insufficient	to	achieve	a	proper	angiogenic	effect,	high	doses	of	these	potent	growth	factors	are	unsafe,	as	they	induce	the	formation	of	 malformed	 vessels.	 Exogenous	 VEGF	 administration	 during	 embryonic	neovascularization	has	resulted	in	the	formation	of	an	abnormal	vascular	network	with	alteration	in	vessel	lumens	(152,	173).	Furthermore,	VEGF	delivery	via	adeno-associated	viral	 vectors	 in	 a	 rabbit	 model	 of	 hind-limb	 ischemia	 efficiently	 promoted	 long-term	angiogenesis.	However,	uncontrolled	VEGF	expression	caused	the	formation	of	vascular	structures	and	fibrosis	in	skeletal	muscles,	suggesting	the	need	to	control	long-term	VEGF	expression	 to	 allow	safe	 VEGF	 therapeutic	 applications	 (174).	 The	 over-expression	 of	VEGF	 in	 the	 hearts	 and	 livers	 of	 transgenic	mice	 resulted	 in	 an	 excessive	 angiogenic	response	 and	 edema	 which	 destroyed	 the	 normal	 architecture	 of	 both	 organs.	 This	outcome	demonstrates	the	lack	of	negative	feedback	loops	for	controlling	and	limiting	VEGF	neovascularization	in	adult	organs	(175).	In	addition,	the	constitutive	expression	of	 VEGF	 in	 the	 skeletal	muscles	 of	mice	 after	 implantation	 of	 retrovirally-transduced	myoblasts	 leads	 to	 the	 increased	 formation	 of	 aberrant-like	 structures	 called	hemangiomas	(176).		Previously,	 our	 group	 investigated	 the	 relationship	 between	 VEGF	dosage	 and	vessel	morphology	and	function	using	a	myoblast-based	delivery	system	to	constitutively	express	heterogeneous	 levels	 of	 VEGF	 in	 the	 skeletal	 muscles	 of	 mice.	 The	 results	demonstrated	 that	 VEGF	 induces	 normal	 or	 aberrant	 angiogenesis	 depending	 on	 its	distribution	in	the	microenvironment	and	not	in	its	total	dose.	In	fact,	decreasing	the	total	number	of	VEGF-expressing	myoblasts	 implanted,	and	therefore	VEGF	dosage,	did	not	prevent	the	formation	of	aberrant-like	structures	due	to	the	presence	of	VEGF	hotspots	
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in	 the	 extracellular	 matrix	 (Fig.	 13).	 However,	 the	 delivery	 of	 myoblasts	 expressing	homogeneous	levels	of	VEGF	showed	the	presence	of	a	threshold	between	normal	and	aberrant	angiogenesis.	Low	and	medium	levels	of	VEGF	induced	the	formation	of	normal	and	 stable	 capillaries	 covered	 by	 pericytes,	 whereas	 high	 levels	 of	 VEGF	 induced	hemangiomas	(Fig.	13)	(176).		The	duration	of	VEGF	expression	is	another	crucial	aspect	to	consider	in	VEGF-mediated	 therapeutic	 angiogenesis.	While	 long-term	VEGF	expression	 is	not	desirable	due	to	its	toxic	effect,	a	too-brief	expression	is	ineffective	in	the	induction	of	a	functional	and	stable	vasculature	(152).	The	importance	of	VEGF	duration	was	demonstrated	in	a	transgenic	model	for	conditional	switching	of	VEGF	expression	in	the	heart	and	liver.	Dor	et	 al.	 have	demonstrated	 that	 early	VEGF	signal	 termination	at	 two	weeks	 caused	 the	complete	regression	of	the	vascular	network	induced	by	VEGF.	However,	prolonged	VEGF	expression	 for	 at	 least	 four	weeks	 resulted	 in	mature	VEGF-independent	 vessels	 that	persisted	after	VEGF	withdrawal	(175).	Consistently,	the	injection	of	inducible	VEGF-AAV	or	VEGF-expressing	myoblasts	 in	skeletal	muscles	 further	confirmed	the	need	for	 four	weeks	 of	 sustained	 VEGF	 expression	 in	 order	 to	 achieve	 stable	 and	 functional	angiogenesis	(177,	178).		Moreover,	 high	 and	 uncontrolled	 expression	 of	 VEGF	 by	 adenoviral	 vector	delivery	 caused	 a	 transient	 VEGF	 expression	 too	 short	 to	 allow	 vessel	 persistency.	However,	 local	 treatment	 with	 Sema3A	 increased	 the	 percentage	 of	 stable	 induced	vessels	at	three	weeks	(154).		In	 conclusion,	 direct	in	 vivo	 gene	delivery	 of	 uncontrolled	 and	 heterogeneous	VEGF	levels	is	unsafe	on	one	hand,	as	it	can	cause	the	formation	of	aberrant	and	unstable	vessels	(176).	On	the	other	hand,	VEGF	expression	must	be	sustained	for	four	weeks	in	order	to	achieve	a	stable	vascular	network	(175).	Therefore,	there	is	the	need	to	develop	
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new	strategies	 for	modulating	 the	 timing	and	dosage	of	 the	growth	 factor	 in	order	 to	increase	the	safety	of	VEGF	gene	delivery	by	enabling	short-term	expression.							.					
	
3.4 PDGF-B	angiogenic	normalization	effects	Targeting	the	process	of	vascular	maturation	 is	a	potential	strategy	 for	modulating	or	balancing	VEGF-induced	angiogenesis	in	order	to	overcome	VEGF	limitations	(152).	The	acquisition	of	a	proper	pericyte	coverage	by	newly-formed	blood	vessels	 is	crucial	 for	vessel	 survival,	 maturation	 and	 stabilization	 (66).	 Among	 the	 factors	 regulating	 the	interplay	between	endothelial	cells	and	pericytes,	PDGF-BB	has	a	primary	role,	as	it	is	responsible	 for	 the	 recruitment	 of	 mural	 cells	 during	 the	 angiogenic	 process.	 Dual	delivery	of	recombinant	VEGF	and	PDGF-BB	from	a	polymer	scaffold	promotes	a	stable	and	dense	vasculature	when	compared	with	VEGF	alone.	The	 latter	 induces	 immature	
Figure	13.	VEGF	induces	normal	or	aberrant	angiogenesis	across	a	microenvironmental	threshold	level.	Lectin	staining	 of	 the	 vasculature	 of	 adult	mouse	 ears	 implanted	 with	 different	 amounts	 of	 VEGF-expressing	myoblasts.	Reduction	in	the	total	dose	of	VEGF	delivered	did	not	prevented	the	formation	of	aberrant-like	structures,	and	bulbous	vascular	 structures	 were	 observed	 even	 in	 the	 presence	 of	 a	 low	 percentage	 of	 myoblasts	 (upper	 image).	Microenvironmental	levels	of	VEGF	produced	by	monoclonal	myoblasts	expressing	homogeneous	VEGF	levels	reveled	a	 threshold	 below	which	 normal	 capillaries	 are	 formed	and	above	which	 hemangioma	are	 induced	 (lower	 image)	(Adapted	from	Ozawa	CR.	et	al,	2004).	
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vessels	and	tissue	edema	(179).	In	a	rabbit	model	of	chronic	hindlimb	ischemia,	venous	infusion	 of	 AAV	 vectors	 carrying	 VEGF	 and	 PDGF-B	 genes	 significantly	 increased	microvascular	maturation	and	collateral	growth	as	well	as	perfusion	and	muscle	function	(180).	 Moreover,	 intramuscular	 adenoviral	 delivery	 of	 VEGF	 and	 PDGF-BB	 from	 two	separate	vectors	caused	the	 formation	of	normal	capillaries.	However,	 the	presence	of	PDGF-BB	could	not	reduce	VEGF-induced	edema	formation	after	six	days.	Notably,	VEGF	and	 PDGF-BB	 co-delivery	 showed	 an	 impairment	 in	 pericyte	 recruitment	 on	 newly-induced	capillaries	compared	with	VEGF	alone.	Most	likely,	the	overexpression	of	PDGF-BB	outside	the	vascular	wall	resulted	in	a	lack	of	PDGF	gradients	from	the	endothelium,	leading	to	pericyte	recruitment	away	from	the	vascular	structures.	Thus,	the	combination	of	 the	 two	 growth	 factors	 enabled	 the	 formation	 of	 longer-lasting	 vessels	 through	paracrine	signals	from	interstitial	recruited	monocytes	and	macrophages.	These	results	suggest	the	importance	of	establishing	co-localized	VEGF	and	PDGF-B	gradients	in	target	tissues	in	order	to	induce	a	proper	vasculature	(181).		Previously,	we	found	that	VEGF	and	PDGF-BB	expression	from	a	single	bicistroic	vector,	 which	 ensures	 a	 co-localized	 expression	 of	 both	 factors	 around	 each	 cell,	prevented	the	formation	of	aberrant	vascular	structures.	Instead,	it	caused	the	formation	of	 normal	 capillaries	 covered	 by	 pericytes,	which	 improved	 blood	 flow	 and	 collateral	vessel	growth	in	a	model	of	hindlimb	ischemia	(182).	Therefore,	co-expression	of	PDGF-BB	normalizes	aberrant	vessels	induced	by	high	and	uncontrolled	VEGF	doses,	allowing	for	the	overcoming	of	the	limitation	of	the	VEGF	dose	and	providing	a	safe	strategy	for	therapeutic	neovascularization.					
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IV. Aim	of	the	thesis	
Peripheral	artery	disease	(PAD)	is	a	chronic	condition	characterized	by	narrowed	arteries	and	decreased	blood	supply	in	the	affected	tissues.	The	disease	mainly	affects	the	lower	 limbs.	 It	 manifests	 clinically	 as	 limb	 claudication	 in	 the	 early	 stages	 and	 can	progress	to	a	more	severe	form	characterized	by	rest	pain	and	tissue	loss	(critical	limb	ischemia)	 (1).	 Morbidity	 and	 mortality	 is	 high	 amongst	 individuals	 affected	 by	 the	disease.	 Although	 lifestyle	 changes	 and	medical	 therapies	 have	 shown	 some	 efficacy,	surgical	and	minimally-invasive	revascularization	are	still	the	mainstays	of	treatment	(2).	However,	current	therapies	for	PAD	are	not	suitable	for	all	patients.	With	the	advent	of	gene,	molecular	and	biotechnological	therapies,	new	strategies	could	be	investigated	in	order	 to	 promote	 the	 formation	 of	 new	 collateral	 arteries	 (arterogenesis)	 and/or	capillaries	(angiogenesis)	and	to	restore	blood	flow	(3).		Vascular	endothelial	growth	factor	(VEGF)	plays	a	crucial	role	in	the	angiogenic	process.	 Consequently,	 it	 is	 widely	 used	 in	 clinical	 trials	 to	 induce	 therapeutic	angiogenesis.	 VEGF	 delivery	 in	 ischemic	 tissues	 has	 been	 associated	 with	 improved	collateral	 artery	 development,	 which	 is	 a	 key	 process	 for	 functional	 recovery	 (4).	Nevertheless,	initial	positive	results	from	clinical	trials	with	VEGF	did	not	demonstrate	any	long-term	functional	improvement.	Additionally,	the	efficacy	of	VEGF	therapy	has	not	been	confirmed	in	placebo-controlled	phase	II	studies.	The	major	obstacle	of	VEGF	gene	therapy	appears	to	be	its	narrow	therapeutic	window.	While	low	doses	are	not	sufficient	to	induce	functional	improvement,	levels	above	a	specific	threshold	are	associated	with	aberrant	vascular	structures	(5).	There	is	thus	the	need	to	precisely	control	the	dose	of	VEGF	delivered	in	vivo.	Several	studies	have	focused	on	the	development	of	alternative	
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strategies	for	better	controlling	the	effects	of	VEGF	doses	in	order	to	induce	normal	and	functional	angiogenesis.	Further,	short-term	expression	of	these	potent	growth	factors	is	desirable	 for	 ensuring	 safe	 angiogenesis.	 However,	 it	 is	 inefficient	 for	 achieving	persistent	 and	 stable	 vessels,	 as	 four	 weeks	 of	 sustained	 expression	 are	 required	 to	achieve	vascular	stabilization	(6).		Notably,	we	previously	found	that	co-expression	of	VEGF	and	PDGF-BB	at	a	fixed	ratio	can	prevent	the	formation	of	aberrant	structures	by	high	and	uncontrolled	VEGF,	suggesting	a	safe	strategy	for	inducing	therapeutic	angiogenesis	with	direct	gene	therapy	(7).	 Moreover,	 we	 recently	 found	 that	 increasing	 VEGF	 doses	 impairs	 vascular	stabilization	 without	 affecting	 pericyte	 recruitment.	 Rather,	 it	 directly	 inhibits	endothelial	 expression	 of	 Sema3A	 and	 leads	 to	 impaired	 Neuropilin-expressing	monocyte	 recruitment	 and	 TGF-β1	 signaling	 in	 the	 endothelium.	 PDGF-BB	 has	 been	shown	 to	 normalize	 aberrant	 angiogenesis	 from	 excessive	VEGF	doses	 by	 stimulating	pericyte	 recruitment.	 However,	 it	 is	 unknown	 whether	 PDGF-BB	may	 also	 affect	 the	stabilization	 kinetics	 of	 VEGF-	 induced	 angiogenesis.	 As	 the	 co-delivery	 of	 PDGF-BB	normalizes	VEGF-induced	vessel	growth,	we	will	investigate	whether	PDGF-BB	may	also	modulate	the	stabilization	of	VEGF-induced	angiogenesis	and	its	underlying	mechanisms.									
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Introduction	Therapeutic	 angiogenesis	 aims	 at	 promoting	 the	 formation	 of	 normal	 and	 functional	capillaries	from	a	preexisting	vascular	network	in	order	to	treat	ischemic	diseases	(1).	Neo-vascularization	by	delivering	exogenous	factors	(i.e.	VEGF)	using	genes,	proteins	or	by	progenitors	cells	delivery	has	shown	promising	results	 in	animal	models.	However	clinical	trials	have	failed	to	demonstrate	a	functional	improvement	in	patients	(2).	VEGF	therapeutic	potential	is	challenged	by	the	need	to	control	both	the	dose	and	duration	of	expression:	sustained	and	uncontrolled	levels	cause	the	growth	of	angioma-like	tumors	(3),	but	transient	delivery	shorter	than	about	4	weeks	is	insufficient	for	stabilization	and	
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persistence	of	induced	vessels	(4).	The	acceleration	of	VEGF-induced	vessels	stabilization	would	therefore	help	increase	the	safety	of	VEGF	gene	delivery	by	enabling	short-term	expression.	The	maturation	of	new	capillaries	is	the	best	understood	mechanism	of	vascular	stabilization.	This	process	 is	characterized	by	the	 investment	of	endothelial	structures	with	pericytes,	which	promote	EC	quiescence	and	make	them	independent	from	further	VEGF	 stimulation	 for	 survival	 (5).	 A	 specific	 population	 of	 BM-derived	myeloid	 cells,	characterized	 by	 co-expression	 of	 the	 monocyte	 marker	 CD11b	 and	 the	 VEGF	 and	Semaphorin3A	 (Sema3A)	 co-receptor	 Neuropilin-1	 (NP1)	 and	 therefore	 named	Neuropilin-Expressing	Monocytes	(NEM),	have	been	shown	to	favor	arteriogenesis	by	the	secretion	of	paracrine	factors	that	promote	smooth	muscle	cell	recruitment	(6).	Recently,	we	 have	 found	 that	NEM	also	play	 a	 crucial	 role	 in	 the	 stabilization	 of	 VEGF-induced	angiogenesis	by	activating	TGF-b1	signaling	through	SMAD2/3.	Further,	increasing	VEGF	doses	impair	vascular	stabilization	without	affecting	pericyte	recruitment,	but	rather	by	directly	 inhibiting	 endothelial	 expression	 of	 Sema3A	 and	 therefore	 impairing	 the	NEM/TGF-β1	axis	(7).	We	previously	found	that	PDGF-BB	co-expression	restores	normal	angiogenesis	despite	high	VEGF	levels,	by	stimulating	pericyte	recruitment	(8).	However,	it	is	unknown	whether	it	may	also	affect	the	stabilization	kinetics	of	VEGF-induced	angiogenesis.	Here,	we	 co-delivered	 specific	 doses	 of	 VEGF	and	PDGF-BB	 in	 skeletal	muscle,	taking	advantage	of	a	highly	controlled	cell-based	gene	delivery	platform,	to	investigate	whether	 PDGF-BB	 could	 accelerate	 the	 stabilization	 of	 VEGF	 dose-dependent	angiogenesis	and	the	underlying	mechanisms.			
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Materials	and	methods	
Cell	Culture	Primary	myoblasts	were	isolated	from	C57BL/6	mice	and	transduced	to	express	the	b-galactosidase	 marker	 gene	 (LacZ)	 from	 a	 retroviral	 promoter	 (9).	 Subsequently	myoblasts	 were	 efficiently	 transduced	 (10)	 with	 retroviruses	 carrying	 the	 cDNA	 of	murine	VEGF164	alone	or	either	with	human	PDGF-BB	linked	through	an	IRES	sequence	(Internal-Ribosome-Entry-Site)	and	a	truncated	murine	CD8a	as	a	marker.	Early	passage	myoblast	clones	were	 isolated	and	characterized	as	previously	described	(11).	Briefly,	myoblasts	clones	were	isolated	using	a	FACS	Vantage	SE	cell	sorter	(Becton-	Dickinson,	Basel,	Switzerland)	and	single	cells	isolation	was	confirmed	visually	(12).	The	stability	of	VEGF	 and	 PDGF-BB	 expression	 was	 assessed	 periodically	 by	 ELISA.	 All	 myoblast	population	were	then	cultured	in	5%	CO2	on	collagen-coated	dishes	with	growth	medium	consisting	 of	 40%	 F-10,	 40%DMEM	 low	 glucose	 (Sigma-Aldrich	 Chemie	 GmbH,	Steinheim,	Germany),	20%	fetal	bovine	serum	(hyClone,	Logan,	UT)	supplemented	with	2.5	ng/ml	basic	fibroblast	growth	factor	(FGF-2),	as	described	(13).			
In	vivo	implantation	of	myoblast	Animal	work	was	carried	out	in	accordance	to	Swiss	federal	guidelines	for	animal	welfare,	after	approval	of	the	veterinary	office	of	the	Canton	of	Basel-Stadt	(Basel,	Switzerland;	Permit	2071).	CB.17	SCID	mice	(Charles	Rivers	Laboratory,	Sulzfeld,	Germany)	of	7-15	weeks	of	age	were	used	for	all	the	experiment	in	order	to	avoid	any	immune	response	to	the	implanted	myoblasts.	Myoblast	were	trypsinized	and	resuspended	in	PBS	with	0.5%	of	BSA	and	1x106	of	cells	were	injected	using	syringe	with	a	291/2-gauge	needle	into	the	tibialis	anterior	and	gastrocnemius	muscle	of	the	mice.	
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Aflibercept	treatment		Mice	were	 injected	 i.p.	with	Aflibercept	 (25mg/Kg;	 100ul)	 in	 PBS	or	with	 the	 vehicle	(100ul	 of	 PBS)	 4	 and	 2	 days	 before	 tissue	 harvesting.	 At	 14	 and	 21	 days	 after	 VEGF	depletion	in	vivo,	muscles	were	harvested	and	processed	to	examine	vessels	stabilization.		
Anti-NRP1A	antibody	treatment	Mice	were	treated	systematically	by	i.p.	injection	with	an	anti-NRP1A	blocking	antibody	(YW64.3,	 Genentech	 Inc.,	 South	 San	 Francisco,	 CA,	 USA)	 (14)	in	 PBS	 with	 0.5%	 BSA	(10mg/kg)	or	with	an	IgG2A	(10mg/kg)	as	control.	Animals	were	treated	at	the	time	of	myoblast	implantation	(day	0)	and	every	3	days	till	the	final	time	point,	according	to	the	previously	published	treatment	schedule	(15).		
Tissue	staining		Mice	 were	 anesthetized	 with	 ketamine	 (100mg/kg)	 and	 Xylazine	 (10mg/kg)	 and	sacrificed	by	intravascular	perfusion	with	1%	paraformaldehyde	in	PBS	pH7.4.	Tibialis	
anterior	 and	 gastrocnemius	 muscles	 were	 harvested,	 post-fixed	 in	 0.5%	paraformaldehyde	for	2	hours	and	then	placed	in	30%	sucrose	overnight	to	cryopreserve	the	tissues.	Muscles	were	embedded	in	OCT,	frozen	in	cold	isopentane	(Sigma)	and	then	cryosectioned	 (10	 μm	 thickness).	 The	 areas	 of	 effect	 corresponding	 to	 myoblast	implantation	 were	 traced	 by	 X-gal	 staining	 (20	 µm)	 in	 adjacent	 serial	 section,	 as	previously	described	 (11).	 Section	of	10	µm	were	 stained	with	 the	 following	primary	antibodies:	 rat	monoclonal	 anti-mouse	 CD31	 (clone	MEC	 13.3,	 BD	Biosciences,	 Basel,	Switzerland)	at	1:100	or	hamster	monoclonal	anti-mouse	CD31	 (clone	2H8,	Millipore,	Merck,	 Germany)	 at	 1:100;	 mouse	 monoclonal	 anti-mouse	 α-SMA	 (clone	 1A4,	 MP	Biomedicals,	Basel,	Switzerland)	at	1:400;	rabbit	polyclonal	anti-NG2	(Millipore,	Merck,	
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Germany)	at	1:200;	rat	monoclonal	anti-CD11b	(clone	M1/70,	Abcam,	Cambridge,	UK)	at	1:100;	 rabbit	 polyclonal	 anti-p-SMAD2/3	 (Santa	 Cruz	 Biotechnology,	 Santa	 Cruz,	 CA,	USA)	at	1:100;	rabbit	polyclonal	anti-Ki67	(Abcam,	Cambridge,	UK)	at	1:100	and	rabbit	polyclonal	 anti-Sema3A	 (Abcam)	 at	 1:50.	 Fluorescently	 labeled	 secondary	 antibodies	(Invitrogen,	Basel,	Switzerland)	were	used	at	1:200.	The	Sema3A	primary	antibody	was	detected	 with	 a	 peroxidase-labeled	 anti-rabbit	 secondary	 antibody.	 The	 first	chromogenic	 signal	 was	 developed	 with	 3,3′-diaminobenzidinetetrahydrochloride	(Sigma).	To	 study	vessel	perfusion	 in	vivo,	mice	were	 injected	with	100	µl	 (1g/ml)	of	FITC-labeled	 Lycopersicon	 esculentum	 lectin	 (Vector	 Laboratories	 Inc.,	 U.S.A)	 into	 the	femoral	vein	and	allowed	to	circulate	for	4	minutes	prior	intravascular	perfusion	(7).	
	
VEGF164	and	PDGF-BB	ELISA	measurements	
The	stability	of	VEGF	and	PDGF-BB	expression	by	myoblasts	was	measured	periodically	during	in	vitro	expansion	of	different	cell	batches.	Myoblasts	were	cultured	in	60	mm	dish	and	subsequently	incubated	4	hours	with	medium	supplemented	with	10 μg/ml	heparin	to	prevent	retention	of	PDGF-BB	on	the	cell	surface.	One	ml	of	medium	was	harvested	then	filtered	and	analyzed	in	duplicate.	Cell	culture	supernatants	(n = 4)	were	quantified	for	mVEGF164	and	hPDGF-BB	protein	using	an	ELISA	kit	(R&D	Systems	Europe,	Abingdon,	UK).	 ELISA	 results	 were	 normalized	 for	 total	 cell	 number	 and	 time	 of	 exposure	 to	medium.		
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RNA	in	situ	hybridization	(ISH)	
Sema3A	and	CD31	mRNA	were	detected	on	frozen	tissue	sections	with	a	sensitive	RNA	in	situ	 hybridization	 (ISH)	 system,	 according	 to	 the	 manufacturer’s	 instructions	(QuantiGene	 ViewRNA,	 Affymetrix	 UK,	 High	 Wycombe,	 UK).	 Briefly,	 muscles	 were	embedded	in	OCT	as	previously	described	followed	by	cryosectioning	(10	μm	thickness)	and	 mounting	 of	 the	 tissue	 onto	 Superfrost	 Plus	 Gold	 glass	 slides	 (Thermo	 Fischer	Scientific,	 Wohlen,	 Switzerland).	 Slides	 were	 kept	 at	 −80°C	 until	 use	 to	 avoid	 RNA	degradation.	 Tissues	 were	 fixed	 with	 4%	 formaldehyde	 overnight,	 washed	 and	dehydrated	 in	ethanol	 for	65	minutes.	Slides	were	boiled	 for	1	min	 in	a	pretreatment	solution	and	treated	with	Protease	QF	(Affymetrix).	Tissue	sections	were	hybridized	for	2	hours	at	40°C	with	target-specific	probes	for	mouse	Sema3A	and	mouse	CD31	mRNAs	(VB1-11132-06	and	VB6-12921-01,	 respectively,	Affymetrix).	As	negative	 control,	one	section	for	each	experiment	was	hybridized	only	in	diluent	without	any	probe	(Probe	Set	Diluent	QT,	Affymetrix).	 Subsequently	each	amplifier	was	hybridized	with	 label	probe	oligonucleotides	conjugated	to	alkaline	phosphatase	(LP-AP)	type	1	or	 type	6,	and	the	probes	were	detected	 respectively	with	Fast	Red	 substrate	 (CD31	detection)	and	Fast	Blue	 substrate	 (Sema3a	 detection).	 Slides	 were	 then	 counterstained	 with	 Meyer’s	hematoxylin	and	DAPI	and	mounted	with	aqueous	mounting	medium	(Dako	Ultramount	Permanent	Mounting	Media	S1964).		
ISH	image	acquisition	and	quantification	The	images	were	acquired	with	a	laser	scanning	confocal	microscope	(LSM710,	Carl	Zeiss	Microscopy,	Göttingen,	Germany)	and	Zen2	software	(Carl	Zeiss	Microscopy).	Between	5	and	10	images	were	acquired	for	each	sample	with	a	40x	objective.	Red	and	green	dots,	
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corresponding	to	the	staining	for	Sema3a	and	CD31	mRNA,	respectively,	were	identified	and	cells	positive	for	either	or	both	transcripts	were	counted	manually	in	each	field.	
	
Vessel	analysis	Vessel	 length	 density	 was	 quantified	 on	 immunofluorescent	 stained	 cryosections	 by	tracing	the	vessel	length	and	dividing	it	by	the	area	were	the	angiogenesis	occurred	(11).	Vessel	stabilization	was	calculated	as	the	fraction	of	vessels	that	persist	after	Aflibercept	treatment,	as	previously	described	(7).			 Infiltrating	CD11b+	cells	were	quantified	on	cryosections	stained	for	endothelium	(CD31)	and	CD11b,	normalizing	the	absolute	number	of	Cd11b+	cells	by	the	area	of	effect.	Vessel	 perfusion	 was	 quantified	 on	 section	 of	 muscles	 harvested	 after	 intravascular	staining	with	fluorescent	lectin,	as	described	above.	After	co-staining	with	an	anti-CD31	antibody,	 the	 total	 length	of	CD31-positive	and	 lectin-positive	vessels	were	quantified	and	vessel	perfusion	index	was	calculated	as	a	ratio	between	the	two	values.			 The	 immunohistochemistry	 staining	 of	 Sema3a	 was	 quantified	 as	 reciprocal	intensity	 by	 the	 standard	 intensity	 function	 in	 the	 open	source	 Fiji	 software	 (ImageJ)	(http://fiji.sc/Fiji)	 as	described	 (16).	Briefly,	 since	 the	maximum	 intensity	value	of	 an	RGB	image	analyzed	 in	 ImageJ	 is	250,	 the	 intensity	of	a	stained	region	of	 interest	was	subtracted	from	250,	thereby	deriving	a	reciprocal	intensity	that	is	directly	proportional	to	 the	 amount	of	 chromogen.	 For	Vessel	 length	 density,	 vessel	 perfusion,	 CD11b+	 cell	recruitment,	 Sema3a	 quantification,	 5-10	 fields	 (20x	 objective)	 were	 analyzed	 per	muscles	 (n=3-4	 muscle/group).	 All	 images	 were	 acquired	 with	 Olympus	 BX61	microscope	 (Olympus,	Volketswil,	 Switzerland),	 and	analyzed	with	CellSense	software	(Olympus,	Volketswil,	Switzerland).		
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	 Pericyte	coverage	was	quantified	after	immunostaining	for	endothelium	(CD31)	and	pericytes	(NG2)	from	5-10	fields	per	muscles	(n=3).	Images	were	taken	with	a	40X	objective	 on	 a	 Carl	 Zeiss	 LSM710	 3-laser	 scanning	 confocal	 microscope	 (Carl	 Zeiss,	Feldbach,	 Switzerland).	 Briefly,	 the	 volume	 of	 CD31	 and	 NG2	 positive	 areas	 were	measured	 with	 Imaris	 software	 (Bitplane	 AG,	 Zurich,	 Switzerland)	 and	 pericyte	maturation	index	was	calculated	as	a	ratio	between	the	two	values	obtained.		
	
Ex-vivo	cell	isolation	by	FACS	Pools	of	8	 limb	muscles	of	SCID	CB17	mice	(Tibialis	anterior	and	Gastrocnemius)	were	harvested	 at	 7	days	 after	myoblast	 injection	 and	 processed	 as	 a	 single	 sample	 (n	=	3	samples/group).	 Tissues	 were	 dissected	 and	 digested	 with	 Collagenase	 type	 II	 at	500U/ml	 activated	with	 CaCl2	 (ThermoFisher	 Scientific)	 for	 30	min	 at	 37°C	 and	 then	mashed	with	a	syringe	plunger.	The	digestion	mix	was	filled	with	PBS	and	centrifuged	at	850	rpm	for	5	min.	The	supernatant	was	discarded	then	Collagenase	D	(Sigma)	at	1.5	U/ml	and	Dispase	at	2.4	U/ml	(ThermoFisher	Scientific)	cocktail	was	added	to	the	digest	supplemented	with	CaCl2	and	incubated	for	1	hour	at	37°C	under	constant	shaking.	The	final	digest	was	centrifuged	and	cells	were	stained	at	4°C	for	30	min	with	the	following	fluorescently	labeled	antibodies:	PE-anti-mouse	CD31	(clone	390;	BioLegend,	San	Diego,	CA,	 USA)	 at	 1:200;	 PE-Cy7-anti-mouse	 CD11b	 (clone	 M1/70,	 BioLegend)	 at	 1:100;	Alexa488-anti-mouse	NG2	(Millipore,	Merck,	Germany).	CD31+,	CD11b+	and	NG2+	cells	were	isolated	with	an	Influx	cell	sorter	(BD	Biosciences).	RNA	was	extracted,	and	gene	expression	analysis	was	performed	as	described	below.	
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Quantitative	Real-Time	PCR	For	RNA	extraction	 from	total	muscles,	mice	were	previously	 injected	with	transgenic	myoblasts	and	muscles	were	freshly	harvested	and	then	disrupted	using	a	Qiagen	Tissue	Lyser	 (Qiagen)	 in	 1	ml	 of	 Tri	 Reagent	 solution	 (Invitrogen).	 The	 RNA	 was	 extracted	according	 to	manufacturer’s	 instructions.	 RNA	 from	 in	 vitro	 endothelial	 cells	or	 FACS	sorted	 cell	was	extracted	with	RNAeasy	Mini	Kit	 (Qiagen).	The	 total	RNA	was	 reverse	transcribed	into	cDNA	with	an	Omniscript	Reverse	Transcription	kit	(Qiagen)	at	37°C	for	60	minutes.	The	quantitative	Real-Time	PCR	was	performed	on	an	ABI	7300	Real-Time	PCR	 system	 (Applied	 Biosystems).	 The	 commercial	 TaqMan	 gene	 expression	 assay	(AppliedBiosystems)	was	 used	 to	 determine	 the	 expression	 of	 genes	 of	 interest.	 The	cycling	parameters	were:	50°C	for	2	minutes,	followed	by	95°C	for	10	minutes	and	40	cycles	of	denaturing	at	95°C	for	15	seconds	an	at	last	annealing/	extension	at	60°C	for	1	minute.	Reactions	were	performed	two	or	three	times	for	each	template,	averaged	and	normalized	to	expression	of	the	GAPDH	housekeeping	gene.		
In	vitro	assay	with	HDMEC	Primary	Dermal	Microvascular	Endothelial	Cells	(HDMEC	-	ATCC	LGS	standards)	were	cultured	according	 to	manufacturer’s	protocol.	Briefly,	primary	endothelial	 cells	were	cultured	with	vascular	cell	basal	medium	(ATCC	LGS	standards)	supplemented	with	0.2	%	 Bovine	 Brain	 Extract,	 5ng/ml	 rhEGF,	 10	 mM	 L-glutamine,	 0.75U/ml	 Heparin	sulfate,1ug/ml	 Hydrocortisone,	 5%	 Fetal	 Bovine	 Serum,	 50ug/ml	 ascorbic	 acid	 and	100U/ml	of	penicillin	/	streptomycin.	Cells	were	seeded	(0.05	x	106/well)	 into	24	cell	culture	plates	and	cultured	at	70%	confluency.	Cells	were	then	starved	for	2	hours	and	stimulated	 for	 24	 hours	 with	 different	 concentration	 of	 hVEGF	 (10ng/ml;	 40ng/ml),	hPDGF-BB	 (2.5ng/ml;	 10ng/ml)	 or	 with	 both	 growth	 factors	 (R&D	 System).	
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Subsequently,	 cells	 were	 collected	 after	 stimulation	 and	 RNA	 extraction,	 reverse	transcription	and	qRT-PCR	was	performed	as	explained	before.	To	quantify	VEGFR2	in	
vitro	 Phosphorylation,	 HDMEC	 were	 seeded	 in	 12-well	 plate	 (0.1x106cells/well)	 and	starved	 overnight.	 Cells	 were	 then	 stimulated	 with	 hVEGF	 (40ng/ml)	 alone	 or	 in	combination	with	hPDGF-BB	(10ng/ml)	for	5	min	and	then	lysed	with	Lysis	Buffer	(Cell	Signaling	Technology)	 supplemented	with	 1	mM	PMSF	 (Sigma)	 for	 5	min	 on	 ice.	 Cell	lysates	were	assayed	 for	VEGFR2	phosphorylation	of	VEGFR2	with	Phospho-VEGFR-2	(Tyr1175)	Sandwich	ELISA	(Cell	Signaling	Technology)	as	described	in	the	manufacturer	protocol.		
	
Statistics	Data	are	presented	as	mean	±standard	error.	The	significance	differences	were	evaluated	with	the	GraphPad	Prism	7	software.	A	normality	test	was	applied	to	each	data	set	and	based	on	data	distribution	we	applied	multiple	comparisons	with	parametric	one-way	analysis	of	variance	(ANOVA)	followed	by	the	Bonferroni	test	or	with	the	nonparametric	Kruskal–Wallis	test	followed	by	Dunn’s	post-test.	Gene	expression	data	were	normalized	by	 logarithmic	 transformation	 (ln=y)	 and	 then	 analyzed	 with	 one-way	 analysis	 of	variance	 (ANOVA)	 followed	 by	 the	 Bonferroni	 test.	 A	 p	 value	 <	0.05	 was	 considered	statistically	significant.							
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Results	
PDGF-BB	co-expression	accelerates	stabilization	of	vessels	induced	by	heterogeneous	
VEGF	levels	To	assess	the	hypothesis	 that	PDGF-BB	co-expression	can	regulate	vessel	stabilization	kinetics,	we	 took	advantage	of	 a	well-characterized	myoblast-gene	delivery	 system	 to	achieve	sustained	expression	of	the	growth	factors	in	skeletal	muscles.	In	order	to	mimic	the	delivery	conditions	of	viral	gene	therapy,	myoblasts	expressing	heterogeneous	and	uncontrolled	levels	of	mVEGF164,	hPDGF-BB	or	both	factors	at	a	fixed	ratio	of	4:1	(VIP)	were	 implanted	 in	 the	 skeletal	 muscles	 of	 adult	 SCID	 mice.	 To	 determine	 VEGF-dependence	 of	 the	 induced	 vasculature,	mice	were	 treated	with	 Saline	 or	 Aflibercept	(VEGF-Trap),	a	potent	VEGF	binder	that	can	deplete	active	VEGF	in	vivo.	As	a	control	we	implanted	myoblast	 expressing	 only	 a	 non-functional	 truncated	 version	 of	 CD8a	 as	 a	surface	marker.	Delivery	of	PDGF-BB	alone	did	not	alter	the	density	of	the	capillary	network	at	any	time	point	with	either	treatment	(Fig.	1B,	1C,	1I	and	1J).	Heterogeneous	levels	of	VEGF	induced	 a	 mixed	 angiogenic	 response	 at	 2	 and	 3	 weeks	 consisting	 of	 both	 aberrant	structures	covered	by	a-SMA+	smooth	muscle	cells	and	normal	capillaries	surrounded	by	NG2+	pericytes	 (Fig.	 1D	 and	 1K).	 As	 expected,	 all	 vascular	 structures	 induced	 by	 co-expression	of	VEGF	and	PDGF-BB	were	morphologically	normal	 capillaries	associated	with	NG2+	pericytes,	despite	uncontrolled	VEGF	levels	(Fig	1F,	1G,	1M	and	1N).	Vessel	Length	Density	(VLD)	was	quantified	after	treatment	with	Aflibercept	or	saline	control	and	vessel	stabilization	was	expressed	as	the	percentage	of	induced	vessels	(i.e.	VLD	in	the	V-	or	VIP-stimulated	tissues	minus	pre-existing	VLD	measured	in	uninjected	control	muscles)	 that	 could	 persist	 independently	 from	 VEGF	 signaling	 (Resistant	 Fraction),	
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according	 to	 the	 mathematical	 equation:	 RF	 %	 =	 ((VLDAflibercept	 -	 VLDCtrl)/(VLDsaline	 -	VLDCtrl))*100.	 In	 the	 saline-treated	mice,	 the	 mean	 VLD	 of	 the	 control	 condition	was	7.5±1.8	 mm/mm2	 and	 values	 above	 control	 VLD	 represent	 newly	 induced	 vessels.	Aberrant	and	normal	vascular	structures	were	quantified	separately.	Aberrant	structures	induced	 by	 uncontrolled	 doses	 of	 VEGF	 were	 completely	 abrogated	 after	 VEGF-Trap	treatment	after	both	2	and	3	weeks,	demonstrating	their	continued	VEGF-dependency.	Normal	capillaries	induced	by	VEGF	alone	caused	an	increase	in	VLD	compared	to	control	conditions	to	58±7.8	mm/mm2	and	50±7.35	mm/mm2,	 respectively	at	2	and	3	weeks.	However,	 after	 VEGF-Trap	 only	 25%	 of	 normal	 vessels	 induced	 by	 VEGF	 alone	were	stable	after	2	weeks	(Fig.1E	and	1P),	with	a	minor	increase	of	the	resistant	fraction	to	38%	 after	 3	 weeks.	 VIP-induced	 capillaries	 yielded	 a	 VLD	 of	 50±10.2	 mm/mm2	 and	47±2.88	 mm/mm2	 after	 2	 and	 3	 weeks,	 respectively.	 In	 contrast	 to	 the	 VEGF	 alone	condition,	already	40%	of	newly	induced	vessels	persisted	after	Aflibercept	treatment	at	2	weeks	(Fig.1G,	1O	and	1P),	with	a	further	increase	of	the	resistant	fraction	to	76%	after	3	weeks	(Fig.	1R).	In	conclusion,	the	co-expression	of	PDGF-BB	significantly	accelerated	vessel	stabilization	compared	to	VEGF	alone,	even	considering	only	the	normal	fraction	of	induced	angiogenesis.				
Experimental	Chapter	
	
 
  90	
	
																		
	
Figure	 1.	 PDGF-BB	 accelerates	 stabilization	 of	 VEGF	 induced	 angiogenesis	 at	 2	 and	 3	 weeks.	 (A-N)	Immunofluorescence	staining	of	endothelium	(CD31,	red),	pericytes	(NG2,	green)	and	smooth	muscles	cells	(α-SMA,	cyan)	on	frozen	section	of	muscles	injected	with	myoblast	expressing	VEGF,	PDGF-BB	or	both	growth	factors	(VIP).	Mice	were	treated	either	with	Saline	of	Afilbercept	at	2	and	3	weeks.	Normal	vessels	display	a	proper	pericyte	coverage,	whereas	aberrant-like	structures	induced	by	heterogeneous	level	of	VEGF	were	covered	with	smooth	muscle	cells.	Scale	bar=	20μm	(O)	Quantification	of	vascular	length	density	(VLD)	and	percentage	of	persistent	vessel	after	Aflibercept	treatment	 (Resistant	 fraction)	 was	 calculated	 at	 2	 and	 3	 weeks.	 The	 highest	 degree	 of	 vascular	 stabilization	 was	observed	 in	 presence	 of	 VEGF	 and	 PDGF-BB	 co-expression	 (P-R).	 VEGFab=aberrant	 angiogenesis	 by	 VEGF	 alone;	VEGFnorm=normal	angiogenesis	induced	by	VEGF;	VIP=	VEGF+PDGF;	PDGF=PDGF-BB	alone.	Data	represent	the	mean	±	SEM	of	individual’s	muscles.	*P	<	0.05	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.		
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Vascular	stabilization	kinetics	depend	on	PDGF-BB	dose	In	order	to	assess	the	role	of	PDGF	-BB	dose	on	the	kinetics	of	vessels	stabilization,	we	used	a	previously	 characterized	pool	of	monoclonal	myoblast	populations,	 genetically	modified	 to	 express	 specific	 doses	 of	 VEGF	 and	 PDGF-BB	 at	 a	 fixed	 ratio	 of	 4:1	 (VIP	clones),	 to	 ensure	 homogeneous	microenvironment	 levels	 (17).	We	 selected	 3	 clonal	populations	based	on	their	in	vitro	expression	of	the	two	growth	factors	at	the	fixed	ratio:	low	 (VEGF	 »10ng/106	 cells/day	 –	 PDGFBB	 »2.5ng/106	 cells/day),	 medium	 (VEGF	
»53ng/106	 cells/day	 –	 PDGFBB	 »13ng/106	 cells/day)	 and	 high	 (VEGF	 »150ng/106	cells/day	 –	 PDGFBB	 »40ng/106	 cells/day).	 Myoblast	 clones	 were	 implanted	 in	 the	skeletal	muscles	of	adult	SCID	mice.	Mice	were	treated	at	2	and	3	weeks	with	Saline	or	Aflibercept,	as	described	before.		All	VIP	 clones	 induced	a	similar	network	of	 capillaries	at	2	and	3	weeks	 in	 the	Saline	 conditions.	 PDGF-BB	 co-expression	 did	 not	 significantly	 increase	 vessel	stabilization	at	low	and	medium	levels	at	2	weeks	compared	to	equivalent	doses	of	VEGF	alone,	as	only	36%	and	23%	of	vessels	persisted	respectively	(Fig.2C,	2E,	2O	and	2P).	However,	in	the	presence	of	high	VEGF	and	PDGF-BB	levels	already	62%	of	the	induced	vessels	 were	 stable.	 By	 3	 weeks	 after	 myoblast	 implantation,	 vessel	 stabilization	gradually	increased	for	both	VIP-low	and	VIP-med	(64%	and	39%,	respectively;	Fig2J,	2L,	2Q	 and	 2R),	 but	 PDGF-BB	 co-expression	greatly	 increased	 vessel	 stabilization	 at	 high	doses	 (95%	Resistant	 fraction;	Fig.2N,	2Q	and	2R).	 In	 conclusion,	 the	 coordinated	co-expression	of	PDGF-BB	promotes	the	stabilization	of	new	induced	vessels,	primarily	at	high	VEGF	levels,	but	not	at	low	and	medium	VEGF	levels.		
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Figure	2.	PDGF-BB	accelerate	vessel	stabilization	only	at	high	doses.	Immunofluorescence	staining	of	endothelium	(CD31,	red),	pericytes	(NG2,	green)	and	smooth	muscles	cells	(α-SMA,	cyan)	of	mice	skeletal	muscles	 injected	with	clonal	population	of	myoblast	expressing	increasing	doses	of	VEGF+PDGF-BB	(VIP).	Mice	were	treated	with	Saline	or	Afilbercept	at	2	and	3	weeks.	All	VIP	clones	induced	normal	capillaries	covered	by	pericytes.	Scale	bar=	20μm	(A-N)	Quantification	of	vessel	length	density	and	vessel	regression	(Resistant	fraction)	was	measured	at	2	and	3	weeks	(VLD)	(O-Q).	Quantification	of	the	resistant	fraction	reveled	that	a	moderate	fraction	of	vessels	induced	by	low	and	medium	doses	of	VIP	were	stable.	However,	the	fastest	stabilization	rate	was	obtained	with	high	VEGF	and	PDGF-BB	levels	both	at	2	and	3	weeks	(P-R).	Data	represent	the	mean	±	SEM	of	individual’s	muscles.	*P	<	0.05	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.	
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Stabilization	 kinetics	 does	 not	 correlate	 with	 differential	 pericyte	 coverage	 or	
vascular	perfusion	Pericytes	 have	 been	 shown	 to	 regulate	 vessel	 maturation	 and	 therefore	 vascular	stabilization	through	their	interaction	with	nascent	endothelial	tubes	(18).	Therefore,	we	sought	to	determine	if	the	differences	in	VIP	stabilization	kinetics	were	correlating	with	changes	in	pericyte	recruitment.	Pericyte	coverage	of	VIP-induced	vessels	was	quantified	two	weeks	after	myoblast	 implantation	 in	skeletal	muscles.	After	 immunofluorescence	staining,	 the	 ratio	 between	 NG2-positive	 area	 and	 CD31-positive	 area	 was	 measured	(maturation	 index).	 All	 conditions	 displayed	 similar	 pericyte	 coverage	 (VIP	 Low	 =	0.51±0.06,	VIP	Med	=	0.47±0.09,	VIP	High	=	0.53±0.02),	demonstrating	that	differences	in	vascular	stabilization	did	not	correlate	with	differential	pericyte	recruitment	(Fig.	3A-D).	 The	establishment	of	blood	 flow	 in	newly	 induced	vessels	 is	 a	 requirement	 for	vessel	remodeling	and	therefore	vessel	maturation	and	stabilization	(19).	Consequently,	observed	differences	in	stabilization	kinetics	could	correlate	with	differences	in	vessel	perfusion.	To	assess	this	hypothesis,	mice	were	injected	4	minutes	prior	sacrifice	with	a	fluorescein-labeled	 lectin	 (FITC-lectin),	 which	 binds	 the	 endothelial	 glycocalyx	 and	therefore	marks	the	lumen	of	vessels	connected	with	the	general	circulation.	The	ratio	between	 lectin-positive	and	CD31-positive	vessel	 length	was	used	to	 identify	perfused	vascular	structure.	As	shown	in	Fig.	3	(E-M),	vessels	induced	by	increasing	doses	of	VEGF	and	 PDGF-BB	 were	 similarly	 perfused	 and	 therefore	 functional	 (Fig.	 3N)	 and	 only	 a	similarly	small	fraction	of	the	new	vascular	bed	was	not	perfused	in	all	conditions.	These	results	 suggest	 that	 differences	 in	 vessel	 stabilization	 rates	 are	 not	 due	 to	 the	establishment	of	a	functional	flow	throughout	the	new	vasculature.		
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Figure	3.	Vessel	stabilization	is	not	associated	with	differences	in	pericytes	recruitment	and	vessel	perfusion.	Immunofluorescence	 staining	 of	 endothelium	 (CD31,	 red)	 and	 pericytes	 (NG2,	 green)	 of	 muscles	 implanted	 with	myoblast	expressing	Low,	Med	and	High	levels	of	VEGF	and	PDGF-BB	at	fixed	ratio	at	2	weeks’	time	point	(a-c).	Size	bar=20μm.	Pericyte	coverage	was	comparable	among	the	conditions	as	demonstrated	by	quantification	of	 the	ratio	between	positive	area	for	CD31	and	NG2	(d).	 Immunofluorescence	staining	of	endothelium	(CD31,	red)	and	lectin-positive	 structures	 (lectin,	white)	 of	mice	muscles	 exposed	 to	 increasing	 doses	 of	 VEGF	 and	PDGF-BB.	Mice	were	injected	 with	 FITC-labeled	 lectin	 prior	 sacrifice	 in	 order	 to	 reveal	 functional	 and	 perfused	 vessels	 (e-m).	 Scale	bar=20μm.	Vessel	perfusion	quantification	showed	that	most	of	the	new	vascular	structures	induced	by	different	VIP	levels	were	perfused	at	2	weeks	(≈	70%	perfused	capillaries)	(n).	Data	from	both	experiments	represent	the	mean	±	SEM	of	individual’s	muscles.	Data	were	subjected	to	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.,	No	significant	difference	was	detected.		
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Increasing	 PDGF-BB	 levels	 up-regulate	 Sema3a	 and	 TGF-b1	 expression	 with	
increased	NEM	recruitment	Recently	 it	 has	 been	 shown	 that	 increasing	 VEGF	 doses	 impair	 vascular	 stabilization	without	 affecting	 pericyte	 recruitment,	 but	 rather	 by	 directly	 inhibiting	 endothelial	expression	 of	 Sema3A	 and	 leading	 to	 impaired	 recruitment	 of	 neuropilin-expressing	monocytes	(NEM)	and	TGF-β1	signaling	in	the	endothelium	(7).	Specifically,	low	VEGF	levels	enable	vessel	stabilization	by	allowing	expression	of	endothelial	Sema3A,	leading	to	robust	NEM	recruitment	and	high	TGF-b1	levels,	which	in	turn	start	a	positive	feedback	loop	 to	 stimulate	 further	 Sema3A	 expression	 and	 maintain	 the	 stabilizing	 signals.	Conversely,	 high	 doses	 of	 VEGF	 impair	 stabilization	 by	 inhibiting	 this	Sema3A/NEM/TGFβ1	axis.	Therefore,	we	sought	to	investigate	whether	the	expression	of	 maturation	 factors	 (Ang-1,	 TGF-b1	 and	 Sema3a)	 governing	 endothelial-pericytes	crosstalk	and	NEM	recruitment	were	differentially	regulated	and	which	might	correlate	with	the	observed	differences	in	VIP	stabilization	rates.	Mice	were	injected	with	control	cells	and	the	different	VIP-expressing	myoblasts	and	gene	expression	was	measured	after	7	days,	when	pericyte-endothelium	crosstalk	is	fully	active	in	nascent	vessels.		As	shown	in	Fig.4A,	different	levels	of	VEGF	and	PDGF-BB	did	not	regulate	Ang1	expression.	Sema3a	and	Tgfb1	were	significantly	up-regulated	with	increasing	doses	of	VEGF	and	PDGF-BB	(Fig.4A),	in	contrast	to	the	effects	of	high	VEGF	alone,	which	caused	instead	a	down-regulation	of	both	 factors	(7).	Specifically,	VIP	High	 increased	Sema3a	expression	5-fold	and	that	of	Tgfb1	9-fold	compared	to	control	levels.	These	data	show	that	the	expression	trends	of	Sema3a	and	Tgfb1	in	presence	of	increasing	doses	of	VEGF	and	PDGF-BB	correlate	with	the	observed	vascular	stabilization	pattern	and	suggest	that	they	 might	 be	 regulated	 directly	 by	 PDGF-BB.	 To	 assess	 this	 hypothesis,	 myoblasts	expressing	 low,	medium	 and	 high	 doses	 of	 PDGF-BB	 alone	were	 implanted	 in	mouse	
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muscles	 and	 the	 expression	 of	 the	 maturation	 factors	 was	 quantified	 after	 7	 days.	Interestingly,	increasing	doses	of	PDGF-BB	alone	caused	an	upregulation	of	Sema3a	and	
Tgfb1	 expression	 in	 total	muscles	 even	 in	 the	 absence	 of	 VEGF	 (Fig.4B),	 suggesting	 a	direct	 regulation	of	Sema3a	expression	by	PDGF-BB.	Gene	expression	data	of	Sema3a	expression	in	the	VIP	conditions	were	confirmed	by	immunostaining	for	Sema3A	protein,	which	 showed	 a	 progressive	 increase	 of	 Sema3A	 in	 the	 tissues	 (Fig.4C-H).	 All	 the	implanted	myoblast	populations	(VIP	and	P	clones)	expressed	low	levels	of	Sema3A	in	
vitro,	 thereby	 excluding	 that	 the	 implanted	 cells	 could	 be	 the	 source	 of	 the	 observed	changes	in	Sema3A	expression	in	vivo	(Fig.4	I-J).																	
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Figure	 4.	TGF-b1	 and	Sema3A	 are	up-regulated	by	 increasing	doses	of	 VEGF	 and	PDGF-BB.	 Gene	expression	analysis	at	7	days	after	implantation	of	myoblasts	expressing	VEGF+PDGF-BB	(VIP	clones),	PDGF-BB	alone	(P	clones)	and	control	cells.	Relative	mRNA	expression	of	Ang1,	Tgfb1	and	Sema3a	was	quantified	by	RT-PCR	and	normalized	to	control	conditions	(A-B).	Tgfb1and	Sema3a	expression	trends	matched	with	the	vascular	stabilization	pattern	in	the	VIP	conditions,	with	a	7-fold	and	4-fold	up-regulation	at	high	VIP	 levels	respectively	despite	high	VEGF	levels	(A).	Interestingly,	delivery	of	PDGF-BB	alone	caused	a	direct	upregulation	of	Sema3A	in	absence	of	VEGF	(B).	Data	represent	the	 mean	 ±	 SEM	 of	 individual’s	 muscles.	 *P	<	0.05,	 **P	<	0.001,	 ***P	<	0.0001	 ANOVA	 with	 Bonferroni	 multiple	comparisons	test,	after	data	normalization	by	logarithmic	transformation.	Immunohistochemistry	for	Sema3A	protein	on	frozen	muscle	sections.	The	intensity	of	Sema3A	was	quantified	as	reciprocal	intensity	on	a	scale	out	of	250.	At	1	week	IHC	staining	confirmed	an	up-regulation	of	Sema3A	expression	by	increasing	VIP	doses	(C-H).	Scale	bar=	50	µm;	Data	 represent	 the	mean	±	SEM	of	 individual’s	muscles.	*P	<	0.05	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	 test.	 Sema3a	 gene	 expression	 was	 performed	 on	myoblast	 expressing	 Low,	 Med	 and	 High	 levels	 of	VEGF+PDGF-BB	or	PDGF-BB	alone	 in	 vitro	 (I-J).	Data	were	 represented	as	 the	mean	±	SEM	of	 individual	 samples.	*P	<	0.05,	**P	<	0.001	***P	<	0.0001	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.	
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NEM	 recruitment	 by	 Sema3A	 was	 previously	 shown	 to	 promote	 vascular	stabilization	(7).	Therefore,	NEM	recruitment	was	assessed	one	week	after	VIP	myoblast	implantation	 by	 immunostaining	 for	 CD11b	 and	 their	 frequency	 was	 quantified	 and	normalized	by	the	area	of	active	angiogenesis	(CD11b+	cells/area	mm2).	As	shown	in	Fig.5	(D,	H,	L	and	M)	a	robust	recruitment	of	NEM	was	detected	in	the	VIP	high	condition	that	correlated	with	increased	expression	of	Sema3a	and	faster	vessel	stabilization.	Cd11b+	NEMs	were	isolated	ex-vivo	by	FACS	in	order	to	investigate	cell-specific	changes	in	gene	expression.	 TGF-b1	 and	NP1	 expression	 by	 CD11b+	 cells	 did	 not	 show	 any	 difference	among	the	groups	(Fig.5N),	in	agreement	with	previous	findings	(7).	Taken	 together,	 these	 results	 suggest	 that	 increasing	VEGF	and	PDGF-BB	doses	might	accelerate	 vascular	 stabilization	 by	 up-regulating	 Sema3A	 expression	 and	 increasing	NEM	recruitment,	which	in	turn	lead	to	an	increased	production	of	TGF-b1	in	the	tissue,	though	 TGF-b1	 expression	 levels	 in	 NEM	 themselves	 were	 not	 directly	 regulated	 by	PDGF-BB	co-delivery.												
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Figure	 5.	 Increasing	 VIP	 doses	 favor	 CD11b+/Nrp1+	 monocyte	 recruitment.	 Immunofluorescence	 staining	 of	endothelial	cells	(CD31,	in	cyan)	and	NEM	(CD11b,	in	red)	1	week	after	injection	of	VIP	myoblast	clones.	Increased	recruitment	of	NEM	is	observed	in	the	VIP	high	condition	that	correlates	with	the	increased	expression	of	Sema3A	(A-L).	Quantification	of	NEM	recruitment	in	the	area	of	VIP-induced	angiogenesis	(CD11b+/mm2).	Data	were	represented	as	the	mean	±	SEM	of	individual’s	muscles.	*P	<	0.05	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test	(M).	CD11b+	cells	were	 isolated	by	FACS	sorting	from	muscles	 injected	with	VIP	Low,	VIP	Med	and	VIP	High.	Gene	expression	data	 relative	 to	GAPDH	showed	 that	TGF-b1	and	Neuropilin-1	were	 similarly	 expressed	by	NEM.	Data	represent	the	mean	±	SEM	of	individual	values.	Data	were	subjected	to	ANOVA	with	Bonferroni	multiple	comparisons	test,	after	data	normalization	by	logarithmic	transformation.	No	significant	difference	was	detected.	
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Increasing	VEGF	and	PDGF-BB	doses	 promote	 endothelium	quiescence	 via	TGF-β1	
pathway		TGF-β1	 is	 known	 to	 regulate	 endothelium	 state	 by	 differentially	 activating	 ALK1	 and	ALK5	 receptors	 (20).	 TGFβ/ALK1	 signaling	 induces	 Smad1/5	 phosphorylation	 and	stimulates	EC	proliferation	and	migration	during	tube	formation	(21).	In	contrast,	TGF-β/ALK5	signaling	stimulates	Smad2/3	pathway,	which	has	been	shown	to	mediate	vessel	maturation	 and	 stability	 through	 inhibition	 of	 EC	 proliferation	 and	 migration	 (20).	Therefore,	 we	 sought	 to	 assess	 whether	 TGF-β	 signaling	 on	 endothelial	 cells	 was	differentially	 regulated	upon	stimulation	with	 increasing	doses	of	VEGF	and	PDGF-BB	and	increased	TGF-b1	expression	in	tissue.	As	shown	in	Fig.6	(A-I)	immunofluorescence	staining	 of	 phosphorylated	 Smad2/3	 complex	 was	 detectable	 in	 EC	 nuclei	 only	 in	presence	of	high	levels	of	VEGF	and	PDGF-BB,	which	cause	the	greater	increase	in	TGF-
b1	levels,	but	not	at	lower	doses.	Consistently,	VIP	doses	increased	dose-dependently	the	expression	of	Serpine1	(PAI-I),	which	is	specifically	induced	by	the	Smad2/3	pathway	and	not	 by	 Smad1/5.	 The	 highest	 Serpine1expression	 (15-fold	 compared	 to	 control)	 was	cause	by	high	levels	of	VEGF	and	PDGF-BB	(Fig.6J).	Instead	the	expression	of	Id1,	which	is	induced	specifically	by	activation	of	the	Smad1/5	pathway,	did	not	change	significantly	among	the	conditions	(Fig.6J).		Furthermore,	the	percentage	of	proliferating	cells	(Ki67+)	was	quantified	in	order	to	confirm	the	observed	differences	in	the	activation	state	of	EC	in	VIP-induced	vessels.	At	7	days,	 vessels	 induced	by	VIP	Low	and	VIP	Med	had	 respectively	25%	and	8%	of	actively	 proliferating	 endothelium.	 Instead	 at	 high	 level	 of	 VEGF	 and	 PDGF-BB,	 the	percentage	of	Ki-67-positive	EC	cells	further	decreased	to	2%,	i.e.	lower	than	the	control	conditions	 (Fig.6	 K-O).	 Therefore,	 these	 data	 show	 that	 VIP	 dose-dependent	 up-regulation	of	TGF-β1	in	the	tissues	caused	the	specific	activation	of	Smad2/3	signaling	
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and	 suppression	 of	 endothelial	 proliferation,	 i.e.	 the	 processes	 that	 favor	 vessel	stabilization.	 																	
		
Figure	 6.	 Increasing	 doses	 of	 VEGF+PDGF-BB	 promote	 endothelial	 cells	 quiescence	 that	 mediates	 vessel	
stabilization.	Immunofluorescence	staining	of	endothelium	(CD31,	green)	and	pSMAD2/3	(violet)	1	week	after	VIP	myoblast	injection	showed	that	TGF-b1	pathway	activity	was	present	only	at	doses	of	VEGF	and	PDGF-BB	(A-I).	Scale	bar=	50µm.	Total	muscles	gene	expression	analysis	revealed	that	Serpine1	(PAI-I)	expression,	induced	by	the	activation	of	Smad2/3,	was	upregulated	by	increasing	doses	of	VEGF+PDGF-BB.	Instead,	the	expression	of	Id1	induced	by	activated	Smad1/5	was	not	 regulated	by	VIP	doses	 (J).	Data	 represent	 the	mean	±	SEM	of	 individual’s	muscles.	 **P	<	0.001,	***P	<	0.0001	 ANOVA	 with	 Bonferroni	 multiple	 comparisons	 test,	 after	 data	 normalization	 by	 logarithmic	transformation.	Immunostaining	for	endothelium	(CD31,	red)	and	proliferating	cells	(Ki67,	green)	at	1	week	(K-N).	The	percentage	of	proliferating	cells	was	quantified	in	the	area	of	VIP-induced	angiogenesis	(O).	VEGF	and	PDGF-BB	co-expression	decreased	dose-dependently	the	total	amount	of	proliferating	endothelial	cells	(K-O).	Data	represent	the	mean	±	SEM	of	individual’s	muscles.	*P	<	0.05	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.	Scale	bar=	20µm.	
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Sema3A/Nrp1	binding	is	required	for	vessel	stabilization	by	PDGF-BB	Neuropilin-1	 (NP1)	 is	 a	 non-tyrosine	 kinase	 receptor	 present	 in	 different	 cell	 types	including	NEM,	which	 can	 act	 as	 a	 co-receptor	 for	 Sema3a	 and	VEGF164/165	 (22).	NP1	receptor	is	essential	for	NEM	recruitment	as	silencing	of	neuropilin-1	by	RNAi	reduced	the	in	vivo	migration	of	CD11b+	cells	in	response	to	VEGF165	and	Sema3A	(6).	Recently,	it	has	been	shown	that	Sema3A	signaling	through	Neuropilin-1	is	required	to	maintain	the	Sema3A/NEM/TGF-β1	 axis	 during	 vessel	 stabilization	 after	 VEGF	 delivery	 (7).	 To	determine	 the	 role	 of	 the	 Sema3A/NEM/TGF-β1	 feedback	 loop	 in	 the	 accelerated	vascular	stabilization	at	high	PDGF-BB	doses,	we	inhibited	Sema3A/NP1	interaction	by	systemic	treatment	with	an	antibody	that	blocks	specifically	the	Sema3A-binding	domain	of	NP1	 (NP1A,	YW64.3,	Genentech),	but	doesn’t	 interfere	with	VEGF	 interactions	 (14),	while	also	abrogating	VEGF	signaling	by	Aflibercept	treatment	to	determine	the	fraction	of	 newly	 induced	 vessels	 that	 had	 successfully	 stabilized	 independently	 of	 Sema3A	signaling.	Adult	SCID	mice	were	implanted	with	myoblast	clones	expressing	high	VEGF	and	PDGF-BB	(VIP	High),	i.e.	the	condition	with	the	fastest	PDGF-BB	induced	stabilization,	or	low	doses	of	VEGF	alone	(V	Low),	i.e.	the	condition	with	the	most	efficient	stabilization	in	the	absence	of	PDGF-BB,	as	well	as	control	myoblasts.	Animals	were	treated	systemically	with	10mg/kg	of	 anti-NP1A	antibody	by	 i.p	 injection	 three	 times	a	week	 (15),	or	with	control	IgG2A.	In	addition,	mice	were	treated	intraperitoneally	with	25mg/kg	Aflibercept	or	saline	twice,	4	and	2	days	before	sacrifice	at	day	21,	as	in	the	previous	experiments	(Fig.	7A).	Both	doses	induced	similarly	normal	and	pericyte-covered	capillary	networks,	as	expected	(Fig.	7B-H).	After	3	weeks	Aflibercept	treatment	showed	that	68%	and	96%	of	the	vessels	induced	by	V	Low	and	VIP	high,	respectively,	were	stable	(Fig.7	C,	E	and	I),	confirming	the	previous	results	described	in	Groppa	et	al.	2015	(7)	and	in	Fig.	2	above.	
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Treatment	 with	 the	 NP1A	 antibody	 significantly	 decreased	 the	 fraction	 of	 persistent	vessels	 in	 both	 cases,	 by	 60%	 with	 VIP	 High	 and	 by	 30%	 with	 V	 Low	 (Fig.	 7J).	Interestingly,	 the	 vessel	 fraction	 that	 could	 stabilize	 independently	 of	 Sema3A/NP-1	signaling	was	the	same	in	both	conditions,	accounting	for	about	30%	of	newly	induced	angiogenesis.	These	results	demonstrate	that	Sema3A/Neuropilin-1	signaling	on	NEM	is	required	for	the	accelerated	vessel	stabilization	induced	by	PDGF-BB	co-delivery.															
Figure	7.	Sema3A/NRP-1	signaling	is	required	for	vascular	stabilization	by	PDGF-BB.	Mice	were	injected	with	VIP	High,	V	Low	and	with	control	myoblast	and	treated	with	AbaNP-1A	and	Aflibercept	as	showed	in	the	diagram	(A).	Mice	were	treated	with	the	two	blocking	antibodies	in	order	to	assess	the	implication	of	Sema3A/TGF-b1/NEM	axis	in	PDGF-BB	stabilization	effect.	Immunostaining	of	the	endothelium	(CD31,	red)	and	pericytes	(NG2,	green),	a-smooth	muscles	cells	(aSMA,	cyan)	on	cryosections	of	muscles	showed	a	decrease	in	VLD	after	VEGF-Trap	and	NP1	blocking	(B-H).	Scale	bar=	 20µm;	Quantification	 of	 vessel	 length	 density	 (VLD)	 and	 resistant	 fraction	 at	 3	weeks	 revealed	 a	 significant	reduction	of	the	fraction	of	stable	vessels	after	the	treatment	with	AbaNP-1A	and	Aflibercept	compare	to	the	treatment	with	 Aflibercept	 and	 IgG2A	 (I-J).	 Data	 were	 represented	 as	 the	 mean	 ±	 SEM	 of	 individual’s	 muscles.	 *P	<	0.05,	**P	<	0.001	by	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.		
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The	effects	of	Sema3A/NP1	interference	on	the	Sema3A/NEM/TGF-β1	feedback	loop	were	evaluated	after	a	1-week	course	of	treatment	with	the	anti-NP1A	antibody	in	the	presence	of	high	VEGF	and	PDGF-BB,	as	described	(7).	The	inhibition	of	Sema3A/NP1	signaling	 essentially	 abolished	 NEM	 recruitment	 induced	 by	 VIP	 High	 compared	 to	controls	(Fig.	8A-E).	As	expected,	the	loss	of	NEM	recruitment	caused	a	down-regulation	of	TGF-β1	and	also	of	Sema3a	expression	in	total	muscles	after	NP1A	treatment	(Fig.	8F-G).	 The	 loss	 of	 Sema3A	 expression	 after	 the	 inhibition	 of	 Sema3A/NP1	 binding	 was	confirmed	at	the	protein	level,	quantified	by	immunostaining	on	frozen	sections	(Fig.	8H-M).	Taken	together,	these	data	suggest	that	PDGF-BB	co-delivery	accelerates	stabilization	of	 VEGF-induced	 angiogenesis	 by	 stimulating	 Sema3A	 expression	 and	 activating	 the	Sema3A/NEM/TGF-b1	 axis	 and	 the	 previously	 described	 TGF-b1/Sema3A	 positive	feedback	loop	(7).														
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Figure	8.	Sema3a/Neuropilin-1	biding	is	required	to	maintain	Sema3a/TGF-b1/NEM	axis	in	presence	of	high	
doses	of	VEGF	and	PDGF-BB.	Immunofluorescent	staining	for	NEM	(CD11b,	red)	and	endothelium	(CD31,	cyan)	at	1	week	on	cryosections	from	muscles	injected	with	VIP	High	and	control	cells.	Mice	were	treated	with	AbaNP-1	or	with	control	IgG2A	(A-D).	Scale	bar=	20µm;	A	reduction	in	NEM	recruitment	in	the	area	of	neo-angiogenesis	was	observed	and	confirmed	by	quantification	of	CD11b+	cells/mm2	(E).	Decrease	in	Sema3a	and	TGFb1	expression	in	total	muscle	after	AbaNP-1	treatment	(F-G).	Immunohistochemistry	of	Sema3A	on	frozen	muscle	sections	confirmed	total	protein	reduction	in	the	tissues	after	blocking	of	Sema3a/NP-1	binding	(H-L).	Quantification	of	Sema3A	protein	intensity	in	the	tissue	(M).	Scale	bar=	50µm;	All	data	are	represented	as	mean	±	SEM	of	individual’s	muscles.	NEM	and	ICH	Sema3A	quantification	 were	 subjected	 to	 ANOVA	 Kruskal-Waills	 with	 Dunn’s	 multiple	 comparisons	 test.	 *P	<	0.05,	
***P	<	0.0001.	RT-PCR	data	were	instead	subjected	to	ANOVA	with	Bonferroni	multiple	comparisons	test,	after	data	normalization	by	logarithmic	transformation.	*P	<	0.05,	**P	<	0.001.	
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PDGF-BB	maintains	endothelial	Sema3a	expression	despite	high	VEGF		We	have	recently	found	that	endothelial	cells	are	the	main	source	of	Sema3A	production	during	VEGF-induced	angiogenesis	and	that	endothelial	Sema3A	is	down-regulated	by	increasing	 VEGF	 doses	 (7).	 To	 investigate	 the	 effect	 of	 PDGF-BB	 co-delivery	 on	endothelial	Sema3A,	its	expression	was	measured	from	endothelial	cells	isolated	ex-vivo	from	tissues	exposed	to	different	VIP	doses.	FACS-sorted	CD31+	cells	expressed	similar	levels	of	Sema3a	 in	 all	 conditions	 (Fig.	9A).	Therefore,	 the	 robust	 increase	 in	Sema3A	detected	 in	 the	 VIP	 High	 tissues	 was	 not	 observed	 in	 CD31+	 cells,	 suggesting	 that	endothelium	might	not	be	the	only	source	of	Sema3A	in	these	conditions.	However,	 it	should	 also	 be	 noticed	 that	 the	 loss	 of	 endothelial	 Sema3a	 expression	 that	would	 be	expected	 in	 the	 presence	 of	 increasing	 VEGF	 doses	 was	 prevented	 by	 PDGF-BB	 co-delivery,	 suggesting	 that	 PDGF-BB	 may	 also	 regulate	 Sema3A	 expression	 directly	 in	endothelial	cells.		In	 order	 to	 investigate	 this	 hypothesis,	 Human	 Dermal	 Microvascular	 Cells	(HDMEC)	were	stimulated	 for	24	hours	 in	vitro	with	two	different	high	doses	of	VEGF	alone	(10	and	40	ng/ml,	respectively),	or	together	with	PDGF-BB	at	a	fixed	1:4	ratio	(2.5	and	 10	 ng/ml	 of	 PDGF-BB,	 respectively),	 or	with	 the	 same	 doses	 of	 PDGF-BB	 alone.	
Sema3a	expression	was	quantified	by	qRT-PCR	after	cell	stimulation.	Both	high	levels	of	VEGF	caused	Sema3A	down-regulation	in	vitro	to	less	than	half	of	the	control	levels,	as	previously	described	(7).	However,	increasing	doses	of	PDGF-BB	alone	significantly	up-regulated	 Sema3a	 compared	 to	 controls,	 showing	 that	 PDGF-BB	 can	 directly	 regulate	Sema3a	expression	by	endothelial	cells	(Fig.	9B).	Furthermore,	co-stimulation	with	VEGF	and	 PDGF-BB	 restored	 Sema3a	 expression	 above	 control	 levels	 despite	 high	 VEGF,	consistently	with	the	results	obtained	with	ex	vivo	isolated	endothelium	(Fig.	9B).	
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These	 data	 suggest	 that	 VEGF	 and	PDGF-BB	 exert	 an	 opposite	 regulation	 on	 Sema3A	expression	 in	 endothelial	 cells.	 In	 order	 to	 start	 investigating	 the	 mechanism	 of	 this	interaction,	we	asked	whether	PDGF-BB	may	interfere	with	VEGF-R2	activation	by	VEGF.	HDMEC	were	treated	with	40	ng/ml	of	VEGF	alone	or	together	with	10	ng/ml	of	PDGF-BB	and	VEGF-R2	phosphorylation	at	the	key	tyrosine	residue	Tyr1175	was	quantified	by	ELISA.	The	results	(Fig.	9C)	show	that	PDGF-BB	co-delivery	did	not	interfere	with	VEGF-R2	 phosphorylation	 by	 VEGF,	 suggesting	 that	 VEGF	 and	 PDGF-BB	 might	 regulate	endothelial	Sema3A	expression	indirectly	through	downstream	signaling	cascades.												
		
Figure	9.	Sema3a	is	restored	in	endothelial	cells	by	PDGF-BB	despite	high	VEGF	levels.	CD31-positive	cells	were	isolated	by	FACS	sorting	from	muscles	injected	with	VIP	clones.	Gene	expression	data	relative	to	GAPDH	showed	that	Sema3A	was	similarly	expressed	by	endothelial	exposed	to	increasing	doses	of	VEGF	and	PDGF-BB	(A).	Primary	human	dermal	microvascular	endothelial	cells	(HDMEC)	were	stimulated	with	increasing	doses	of	VEGF,	PDGF-BB	alone	and	VEGF+PDGF-BB	for	24	hours.	Sema3A	expression	was	quantified	by	RT-PCR	and	normalized	for	non-treated	cells.	VEGF	inhibited	 Sema3A	 expression	 whereas	 PDGF-BB	 up-regulated	 it.	 Co-expression	 of	 PDGF-BB	 restored	 Sema3A	expression	by	endothelial	cells	(B).	Data	represent	the	mean	±	SEM	of	individual	values.	All	data	were	subjected	to	ANOVA	 with	 Bonferroni	 multiple	 comparisons	 test,	 after	 data	 normalization	 by	 logarithmic	 transformation.	
***P	<	0.0001.	HDMEC	were	treated	with	VEGF	alone	or	in	combination	with	PDGF-BB,	VEGF-R2	phosphorylation	was	quantified	by	ELISA.	PDGF-BB	co-stimulation	did	not	affect	VEGFR	phosphorylation	by	VEGF	(C).	Data	represent	the	mean	±	SEM	of	individual	values.	Data	were	subjected	to	ANOVA	with	Bonferroni	multiple	comparisons	test,	after	data	normalization	by	logarithmic	transformation.	***P	<	0.0001.	
C 
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PDGF-BB	dose-dependently	increases	non-endothelial	sources	of	Sema3a	Gene	expression	data	from	ex	vivo-sorted	endothelial	cells,	as	well	as	from	in	vitro	studies,	demonstrated	 that	 PDGF-BB	 prevents	 Sema3A	 down-regulation	 by	 high	 VEGF	 levels.	Nevertheless,	 endothelial	 Sema3A	 expression	 was	 not	 significantly	 increased	 with	increasing	VIP	doses,	contrary	to	the	total	Sema3A	amount	quantified	in	total	muscles	(Fig.	4).	In	order	to	identify	potential	non-endothelial	sources	of	Sema3a	expression	and	their	relative	contribution	compared	to	endothelium,	we	performed	fluorescent	in	situ	hybridization	(FISH)	on	frozen	section	to	co-detect	Cd31	mRNA	and	Sema3a	mRNA.	The	total	amount	of	cells	expressing	both	Sema3a	(red	signal)	and	Cd31	mRNA	(green	signal)	or	only	Sema3a	was	quantified	in	tissues	harvested	one	week	after	implantation	of	VIP	Low,	Medium	and	High	myoblast	clones.	As	shown	in	Fig.	10,	the	majority	of	the	Sema3a	transcript	was	detected	in	EC	(about	200-500	cells/mm2)	compared	to	non-endothelial	cells,	 ranging	 from	 about	 50	 to	 150	 cells/mm2.	 However,	 the	 amount	 of	 Sema3a-expressing	endothelial	cells	did	not	show	a	clear	dose-dependent	trend	(Fig.	10M,	p=n.s.),	confirming	the	 in	vitro	and	ex	vivo	 results	above.	On	the	contrary,	 the	non-endothelial	fraction	of	Sema3a	expressing	cells	was	clearly	expanded	by	increasing	VIP	doses	(Fig.	10N;	 p<0.05),	 accounting	 for	 about	 ⅓	 of	 the	 total	 Sema3a-expressing	 cells	 (≈150	cell/mm2)	in	the	presence	of	high	levels	of	VEGF	and	PDGF-BB,	which	induce	the	fastest	vascular	 stabilization.	 Furthermore,	 we	 observed	 from	 FISH	 images	 that	 the	 non-endothelial	cells	expressing	Sema3A	were	located	in	proximity	of	endothelium	(Fig.	11),	suggesting	a	peri-vascular	identity.			
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Figure	10.	Sema3a	is	expressed	manly	by	the	endothelium.	In	situ	hybridization	for	CD31	transcript	(green)	and	
Sema3a	transcript	(red)	on	frozen	muscles	injected	with	increasing	doses	of	VEGF+PDGF-BB.	Arrows	indicates	cells	expressing	either	transcripts	(yellow)	or	only	Sema3A	(red)	(A-L)	Scale	bar=	20μm;	Quantification	of	the	total	number	of	endothelial	cell	(EC)	or	non-endothelial	cells	(NEC)	expressing	Sema3a	in	the	area	of	effect	(M-N).		Data	represent	the	mean	±	SEM	of	10	 individual	 fields	of	view	from	independent	muscles	(n=3).	*P	<	0.05	Data	were	subjected	to	ANOVA	Kruskal-Waills	with	Dunn’s	multiple	comparisons	test.		
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In	conclusion,	these	data	show	that	PDGF-BB	increases	non-endothelial	sources	of	Sema3a	 expression,	 but	 not	 endothelial	 ones.	The	 cellular	 identity	 of	 non-endothelial	Sema3A	sources,	as	well	as	the	effects	of	PDGF-BB	on	their	levels	of	Sema3A	expression	and	the	underlying	mechanisms,	remain	to	be	investigated.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	11.	Sema3A-expressing	NECs	are	located	in	proximity	of	the	vessels.	In	situ	hybridization	(for	CD31	and	
Sema3a)	images	at	higher	magnification.	NEC	source	expressing	Sema3A	seems	to	be	located	near	CD31-positive	cells	(marked	by	the	dash	line).	Size	bar=20μm	
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Discussion	Therapeutic	 angiogenesis	 by	 VEGF	 gene	 therapy	 aims	 to	 promote	 the	 formation	 of	functional	vessels	properly	connected	to	the	pre-existing	vasculature.	VEGF	therapeutic	potential	 is	 challenged	 by	 the	 need	 to	 control	 both	 dose	 and	 duration	 of	 expression.	Moreover,	it	has	been	shown	that	sustained	and	uncontrolled	levels	cause	the	growth	of	angioma-like	tumors,	but	transient	delivery	shorter	than	about	4	weeks	is	insufficient	for	stabilization	 and	 persistence	 of	 induced	 vessels	 (4).	We	 previously	 demonstrate	 that	VEGF	and	PDGF-BB	balanced	co-expression	from	a	single	bicistronic	vector	switch	the	formation	of	vascular	tumors	 induced	by	VEGF	overexpression	 into	normal	capillaries	overcoming	VEGF	dose	limitation	(8).	Recently	it	was	found	that	increasing	VEGF	doses	impair	 vessels	 stabilization	 by	 inhibiting	 the	 endothelial	 Semaphorin3A/Neuropilin1-expressing	monocytes	(NEM)/TGF-β1	paracrine	axis	(7).		Here	we	found	that	PDGF-BB	dose-dependently	accelerates	stabilization	of	VEGF-induced	 vessels,	without	 affecting	 pericyte	 recruitment,	 but	 rather	 by	 stimulating	 the	Sema3A/NEM/TGF-β1	 signaling	 axis	 (Fig.	 12).	 Our	 data	 showed	 that	 PDGF-BB	 co-delivery	significantly	improved	stabilization	of	vessels	induced	by	uncontrolled	levels	of	VEGF	(Fig.	1).	Moreover,	when	analyzing	the	dose	effects	of	PDGF-BB	we	observed	that	PDGF-BB	co-expression	did	not	change	the	effects	at	low	and	medium	VEGF	levels,	but	it	greatly	accelerated	vascular	stabilization	at	high	VEGF	(90%	of	stable	vessels	at	3	weeks	vs	0%	with	VEGF	alone)	(Fig.	2).	The	physical	association	between	pericytes	and	nascent	vascular	tubes	is	crucial	for	 vascular	 maturation	 and	 stabilization	 (23).	 Disruption	 of	 endothelial-pericyte	associations	by	VEGF	overexpression	or	genetic	ablation	of	PDGF-B/PDGFRb	 signaling	during	development,	results	in	abnormal	vascular	remodeling,	instability	and	regression	
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(24,	25).	Vessels	 induced	by	 increasing	doses	of	VEGF	and	PDGF-BB	displayed	similar	pericyte	 coverage	 despite	 clearly	 different	 stabilization	 kinetics	 (Fig.	 3).	 Although	pericytes	are	essential	for	vessel	maturity,	their	simple	physical	presence	on	endothelial	structures	 is	 not	 sufficient	 to	protect	 vessels	 from	 regression	 after	 VEGF	withdrawal.	Therefore	pericyte-independent	mechanisms	exist	to	regulate	the	stabilization	of	newly	formed	vessels.	Several	 lines	of	evidence	show	that	blood	flow	shear	stress	and	blood	pressure	affect	vascular	remodeling	and	maturation	(26,	27).	As	the	establishment	of	blood	flow	can	 favor	 vessel	maturation	 and	 consequently	 their	 stabilization,	 the	 rate	 of	 vascular	perfusion	was	quantified	at	increasing	doses	of	VEGF	and	PDGF-BB,	but	no	differences	could	be	observed	among	the	conditions	(Fig.	4).	In	recent	years,	Sema3A	role	in	angiogenesis	has	garnered	growing	interest,	as	it	is	 important	 for	 endothelial	 cell	migration	 and	 survival	 in	 vitro	 as	well	 as	 for	 tumor-induced	angiogenesis	in	vivo	(28).	Moreover,	several	reports	have	demonstrated	that:	I)	 Sema3A	 signaling	 through	 neuropilin	 results	 in	 a	 greater	 pericyte	migration	 and	vascular	remodeling	while	normalizing	tumor	angiogenesis	(29,	30);	 II)	Sema3A	is	a	chemoattractant	 for	 circulating	 monocytes	 called	 NEM	 (neuropilin-expressing	monocytes),	which	have	been	shown	to	favor	arterial	formation	in	a	paracrine	fashion	(6).	Previous	studies	in	our	lab	revealed	that	low	doses	of	VEGF	enable	efficient	vascular	stabilization	by	allowing	high	expression	of	endothelial	Sema3A,	leading	to	robust	NEM	recruitment	and	high	TGF-b1	levels,	which	on	one	hand	stabilize	endothelial	structures	by	activating	Smad2/3	signaling,	and	on	the	other	hand	start	a	novel	positive	feedback	loop	 to	 stimulate	 further	 Sema3A	 expression,	which	maintains	 the	 stabilizing	 signals.	Conversely,	 high	 doses	 of	 VEGF	 impair	 stabilization	 by	 inhibiting	 the	Sema3A/NEM/TGFβ1	 axis	 (7).	 Here	 we	 observed	 that	 PDGF-BB	 co-delivery	 restored	
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Sema3A	 and	 TGF-b1	 expression	 that	 normally	 were	 abolished	 by	 high	 VEGF	 doses,	suggesting	 that	 PDGF-BB	 may	 accelerate	 vascular	 stabilization	 also	 by	 modulating	Sema3A	expression.	The	expression	 trends	of	Sema3A	and	TGF-b1	 in	 the	presence	of	increasing	 doses	 of	 VEGF	 and	 PDGF-BB	 matched	 the	 vascular	 stabilization	 pattern	previously	observed	in	conditions	of	low	VEGF	(Fig.	4).	In	agreement	with	the	levels	of	Sema3A	expression,	 an	 increase	 recruitment	of	NEM	was	observed	 in	 the	presence	of	high	levels	of	VEGF	and	PDGF-BB	(Fig.	5).	TGF-b1	 is	 a	 pleiotropic	 cytokine,	 which	 can	 either	 inhibit	 EC	 migration	 and	proliferation	 promoting	 vessel	 stabilization	 through	 ALK5	 receptor	 signaling	 via	Smad2/3,	 or	 simulate	 endothelium	 activation	 through	 TGF-β/ALK1	 pathway	 and	Smad1/5	phosphorylation	(31).	Moreover,	TGF-β	dose	can	balance	the	activation	state	of	the	 endothelium	 via	 activation	 of	 ALK1	 or	 ALK5:	 low	 doses	 of	 TGF-β	 triggers	 ALK1	activation	and	stimulate	EC	proliferation	and	migration,	while	high	doses	of	TGF-β	inhibit	these	responses	via	ALK5	(32).	Consistently,	in	the	presence	of	high	doses	of	VEGF	and	PDGF-BB,	which	showed	a	faster	vascular	stabilization,	TGF-b1	was	highly	upregulated	and	 it	 promoted	 Smad2/3	 phosphorylation	 and	 upregulation	 of	 Smad2/3	 specific	downstream	 gene	 PAI-1,	 thereby	 stimulating	 vessel	 stabilization	 (Fig.	 6).	 Increased	endothelial	cells	quiescence	with	VIP	high	was	additionally	confirmed	by	Ki67	staining.		To	 further	 confirm	 that	 the	 Sema3A/NEM/TGF-b1	 axis	 is	 responsible	 for	 the	PDGF-BB-induced	 acceleration	 of	 vessel	 stabilization	 we	 inhibited	 Sema3A-mediated	recruitment	of	NEM	by	preventing	Sema3A	interaction	with	the	co-receptor	neuropilini-1	 on	 NEM.	 The	 blocking	 antibody	 anti-NP1A	 specifically	 interferes	 with	 the	 binding	between	NP-1	and	Sema3A,	but	not	with	VEGF	(14,	15).	The	condition	with	 low	VEGF	levels,	which	has	been	 shown	 to	promote	 the	 fastest	 stabilization	under	 conditions	of	
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VEGF	 alone	 through	 the	 Sema3A/NEM/TGF-b1	 axis,	 was	 used	 as	 positive	 control.	Blocking	of	Sema3A/NP-1	binding	drastically	reduced	vascular	stabilization	by	both	low	VEGF	alone	and	even	more	in	the	presence	of	high	VEGF	and	PDGF-BB	(Fig.	7).	Nearly	70%	of	the	vessels	induced	by	VEGF	and	PDGF-BB	co-delivery	regressed,	suggesting	that	the	Sema3A/NEM/TGF-b1	axis	is	crucial	for	PDGF-BB	mediated	acceleration	of	vascular	stabilization.	Interestingly,	however,	both	conditions	(V	Low	and	VIP	High)	exhibited	a	similar	fraction	of	resistant	vessels	of	about	30%	after	Sema3A/NP-1	blockade,	despite	starting	 from	 rather	 different	 stabilization	 rates	 (68%	 and	 96%,	 respectively).	 This	similar	fraction	of	Sema3A-	and	NEM-independent	vessel	stabilization	is	regulated	by	a	different	mechanism	and	it	is	tempting	to	speculate	that	this	may	be	pericyte-dependent,	as	 in	 fact	pericyte	recruitment	did	not	vary	among	these	conditions.	Moreover,	in	vivo	neuropilin-1	 blockade	 at	 7	 days	 caused	 a	 reduction	 in	NEM	 recruitment,	 TGF-b1	 and	Sema3A	 expression,	 confirming	 that	 the	 TGF-b1/Sema3A	 positive	 feedback	 loop	mediates	also	VIP-induced	vascular	stabilization	(Fig.	8).	Sema3A	is	mainly	expressed	by	endothelial	cells	and	it	regulates	endothelial	cells	migration	and	vessel	remodeling	(33).	However,	it	remains	to	be	completely	elucidated	how	PDGF-BB	regulates	Sema3A	expression	by	endothelial	cells.	Interestingly,	increasing	doses	of	PDGF-BB	alone	caused	an	upregulation	of	Sema3A	expression	in	vivo	even	in	the	absence	of	VEGF,	suggesting	a	possible	direct	regulation	of	Sema3A	expression	by	PDGF-BB	 (Fig.	 4).	 Consistently,	 PDGF-BB	 dose-dependently	 stimulated	 endothelial	 Sema3A	expression	 in	 vitro,	 whereas	 increasing	 doses	 of	 VEGF	 impair	 Sema3A	 expression.	Additionally,	 in	 vitro	VEGF	and	PDGF-BB	co-stimulation	of	 endothelial	 cells	prevented	loss	of	Sema3A	expression	despite	high	VEGF	levels	(Fig.	9).	Based	on	these	observations,	we	 reasoned	 that	 PDGF-BB	 may	 compete	 with	 VEGF	 in	 the	 regulation	 of	 Sema3A	
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expression	 by	 endothelial	 cells.	 However,	 VEGF	 and	 PDGF-BB	 co-stimulation	 of	endothelial	 cells	 in	 vitro	 did	 not	 interfere	 with	 VEGF-dependent	 VEGFR2	phosphorylation,	although	it	can’t	be	excluded	that	PDGF-BB	may	act	through	VEGFR2	(Fig.	9C).	Recently,	Mamer	and	coworkers	identified	and	measured	novel	PDGFs	to	VEGF-R	interactions	utilizing	surface	plasmon	resonance.	They	proved	that	PDGF-BB	can	bind	VEGFR2	with	a	KD=40	nM,	and	this	cross-family	interaction	can	expand	the	role	of	these	growth	factors	in	angiogenesis.	In	a	cross-family	signaling	system,	ligands	can	compete	to	bind	the	same	receptors	and	ligand	concentration	as	well	as	ligand-receptor	binding	kinetics	 may	 determine	 which	 ligand(s)	 is	 dominating	 the	 signaling	 (34).	 Moreover,	PDGF-BB	can	physically	interact	with	NP1	(35).	Thus,	additional	in	vitro	assays	such	as	blocking	of	VEGFR2,	PDGFRa	or	NP1	after	stimulation	with	PDGF-BB	are	necessary	to	better	elucidate	Sema3A	regulation	of	expression	by	endothelial	cells.	
Ex-vivo	endothelial	Sema3a	expression	data	and	fluorescent	in	situ	hybridization	for	Sema3A	revealed	that	endothelial	cells	are	not	the	only	source	of	the	glycoprotein.	In	fact,	 increasing	 doses	 of	 VEGF	 and	 PDGF-BB	 promoted	 Sema3A	 expression	 by	 a	population	 of	 non-endothelial	 cells	 (NEC)	 (Fig.	 10).	 Further,	 FISH	 data	 showed	 that	
Sema3a-positive	NEC	were	localized	near	the	vessels	in	the	areas	of	effects.	Recently,	it	has	been	shown	that	satellite	cells	can	express	Sema3A	in	response	to	hepatocyte	growth	factor	(36). However, the	non-endothelial	source	of	Sema3A	that	we	observed	and	that	is	stimulated	by	PDGF-BB	remains	still	to	be	identified.	In	 conclusion,	 we	 showed	 that	 PDGF-BB	 co-delivery	 both	 prevents	 loss	 of	endothelial	 Sema3A	 expression	 induced	 by	 high	 doses	 of	 VEGF	 and	 expands	 a	 non-endothelial	population	of	Sema3a-expressing	cells.	These	combined	actions	boost	NEM	recruitment,	leading	to	high	level	of	TGF-β1	in	the	tissue.	TGF-β1	acts	through	Smad2/3	signaling	 in	 endothelial	 cells	 to	maintain	 the	endothelium	 in	 a	 quiescent	 state,	which	
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favors	 vessels	 stabilization,	 while	 further	 stimulating	 Sema3A	 production	 by	endothelium	 in	a	pro-stabilization	positive	 feedback	 loop.	PDGF-BB	plays	an	essential	role	 in	 pericyte	 recruitment	 and	 vessel	maturation.	 However,	 here	we	 found	 a	 novel	pericyte-independent	 function	 of	 PDGF-BB	 in	 promoting	 vessel	 stabilization	 by	stimulating	Sema3A	expression	to	start	the	NEM/TGF-b1/Sema3A	stabilizing	feedback	loop	 previously	 described.	 Therefore,	 PDGF-BB	 co-delivery	 represents	 a	 promising	strategy	for	therapeutic	angiogenesis	as	it	allows	to	overcome	both	main	limitations	of	VEGF	 delivery:	 1)	 PDGF-BB	 normalizes	 VEGF-induced	 angiogenesis	 expanding	 VEGF	therapeutic	window;	 and	 2)	 it	 accelerates	 vascular	 stabilization	 through	 Sema3A	 up-regulation,	NEM	recruitment	and	TGF-b1	release,	enabling	a	safe	short-term	VEGF	gene	therapy.	
										
	
Figure	12.	PDGF-BB	accelerates	stabilization	of	VEGF-induced	vessels	through	Sema3A/NEM/TGb1	axis.	High	levels	of	VEGF	impair	vascular	stabilization,	whereas	PDGF-BB	co-delivery	restored	Sema3A	expression	by	endothelial	cells	 and	 stimulate	 Sema3A	 expression	 by	 non-endothelial	 cells.	 Sema3A	 upregulation	 promote	 significantly	NEM	recruitment	 and	 TGF-b1	 expression.	 High	 levels	 of	 TGF-b1	 acts	 through	 ALK5	 and	 Smad2/3	 pathway	 to	 favor	endothelium	quiescence.		
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VI. Summary	and	Futures	Prospective		
Peripheral	 artery	 disease	 (PAD)	 affects	 over	 200	millions	 of	 adults	 and	 remains	 the	leading	 cause	 of	 premature	 death	 worldwide.	 This	 condition	 is	 the	 results	 of	atherosclerosis,	 in	 which	 atherosclerotic	 plaque	 can	 harden	 and	 narrow	 the	 arteries	limiting	blood	flow	to	the	 limbs	(1).	PAD	that	can	results	in	a	most	severe	 form	called	critical	limb	ischemia,	characterized	by	pain	during	walking	(claudication),	gangrene	and	in	 some	 cases	 limb	 amputation	 (2).	 Although	 patients	 with	 PAD	 are	 treated	 with	 a	combination	of	risk	factor	modification,	such	as	anticoagulants,	vasodilators,	angioplasty	and	cathether-mediated	procedures,	these	treatments	cannot	be	applied	to	all	patients.	To	 overcome	 this	 limitation,	 therapeutic	 angiogenesis	 has	 emerged	 as	 a	 potential	alternative	 to	 promote	 vascularization	 of	 poorly	 perfused	 ischemic	 tissues	 (3,	 4).	Therapeutic	angiogenesis	can	be	achieved	via	delivery	of	pro-angiogenic	growth	factors	in	 the	 form	 of	 recombinant	 protein,	 gene	 therapy,	 or	 by	 cell-based	 delivery,	 such	 as	administration	of	endothelial	progenitor	cells	(5).		The	delivery	of	Vascular	Endothelial	Growth	Factor	in	ischemic	tissues	has	been	associated	 with	 improved	 collateral	 artery	 development,	 which	 is	 a	 key	 process	 for	functional	 recovery	 (6).	VEGF	 is	 the	major	player	during	 the	angiogenic	process,	 as	 it	mediates	 endothelial	 cell	 migration	 and	 proliferation	 becoming	 one	 of	 the	 most	important	molecular	target	for	therapeutic	angiogenesis	(7).	VEGF	therapy	has	showed	promising	results	in	animal	models	but	failed	to	prove	significant	therapeutic	efficacy	in	clinical	trials	(8).	Among	the	reasons	for	VEGF	therapies	failure	we	can	identify	two	main	issues:	 dose	 and	 duration	 of	 VEGF	 expression.	 In	 fact,	 it	 has	 been	 shown	 that	 its	expression	period	 should	 be	 sustained	 enough	 (4	weeks)	 to	 achieve	 the	 formation	 of	
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functional	 and	 stable	vessels	 (9),	however	excessive	expression	of	 this	potent	growth	factor	rises	safety	concerns,	as	uncontrolled	levels	of	VEGF	can	promote	the	formation	of	aberrant	vessels	and	angioma-like	tumors	(10).		We	 previously	 found	 that	 balanced	 co-expression	 of	 VEGF	 and	 PDGF-BB	 can	prevent	 the	 issues	 of	 excessive	 localized	 VEGF	 doses	 normalizing	 VEGF-mediated	aberrant	vascular	growth	(11).	As	PDGF-BB	co-delivery	showed	to	harness	the	potency	of	VEGF	by	preventing	its	toxic	effects	we	decided	to	investigate	whether	PDGF-BB	co-expression	could	also	positively	modulate	the	stabilization	of	VEGF-induced	vessels.	Taking	advantage	of	a	myoblast	gene-delivery	system	to	provide	heterogeneous	levels	of	VEGF	alone	or	with	PDGF-BB	we	found	that	PDGF-BB	co-expression	not	only	normalized	 VEGF-induced	 vessels	 but	 significantly	 accelerate	 vascular	 stabilization.	However,	when	analyzing	the	dose	effects	of	VEGF	and	PDGF-BB	co-delivery	on	the	time-course	of	vessels	stabilization	we	discovered	that	normal	vessels	induced	by	low,	medium	and	 high	doses	 of	 VEGF	 and	PDGF-BB	presented	 similar	 pericyte	 coverage	 and	 blood	perfusion	 but	were	 stabilizing	 differently.	 In	 fact,	 the	 greatest	 stabilization	 effect	was	observed	 only	 at	 high	 doses	 of	 the	 two	 growth	 factors,	 demonstrating	 that	 simply	pericyte	coverage	was	not	sufficient	to	achieve	maximum	vascular	stabilization.	Rather	we	 found	 evidence	 for	 a	 pericyte-independent	 function	 of	 PDGF-BB	 in	 regulating	 the	Sema3A/NEM/TGF-b1	 signaling	 axis,	 which	we	 previously	 identified	 to	 contribute	 to	vascular	stabilization	after	delivery	of	VEGF	alone	and	to	be	disrupted	by	increasing	VEGF	levels	(12).		Here	we	demonstrated	that	PDGF-BB	restored	Sema3A	expression	despite	high	levels	of	VEGF.	Sema3A	upregulation	 in	turn	promoted	NEM	recruitment,	which	exert	their	stabilizing	effect	by	promoting	endothelial	quiescence	through	TGF-b1/SMAD2/3	signaling,	achieving	a	stable	vascular	fraction	of	90%	already	at	3	weeks	with	VEGF	and	
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PDGF-BB	co-expression.	The	abrogation	of	Sema3A	binding	on	NEM	by	a	specific	blocking	antibody	 resulted	 in	a	dramatic	 reduction	of	vessel	 stabilization,	 Sema3A	and	TGF-b1	expression	 as	well	 as	 NEM	 recruitment	 confirming	 that	 PDGF-BB	 accelerate	 vascular	stabilization	by	modulating	Sema3A/NEM/TGF-b1	axis.	Interestingly,	we	discovered	that	in	the	presence	of	PDGF-BB	co-delivery	Sema3A	was	not	produced	only	by	the	endothelium,	and	PDGF-BB	dose-dependently	expanded	the	non-endothelial	population	of	 Sema3A-expressing	 cells,	while	 it	did	not	affect	 the	amount	Sema3A+	endothelial	cells.	Therefore,	it	will	be	interesting	to	determine	which	non-endothelial	population/s	are	a	PDGF-BB-responsive	source	of	Sema3A.	Therefore,	the	isolation	of	endothelial	cells,	pericytes,	satellite	cells	and	myeloid	cells	from	muscles	injected	with	different	VEGF	and	PDGF-BB	doses,	and	the	subsequent	analysis	of	Sema3A	expression	by	qRT-PCR,	will	allow	us	to	define	quantitatively	and	qualitatively	the	source	of	 the	 glycoprotein.	 On	 the	 other	hand,	 little	 is	 known	of	 how	PDGF-BB	 restores	 and	regulate	Sema3A	expression	by	endothelial	cells.	Therefore,	it	is	necessary	to	assess	the	mechanism	of	PDGF-BB	regulation	of	Sema3A	expression	in	endothelial	cells	in	vitro.		Several	lines	of	evidence	suggest	that	Sema3A	can	mediate	pericyte	recruitment,	thereby	reducing	tumor	growth	and	normalizing	tumor	angiogenesis	(13).	Furthermore,	Jurisic	 et	 al	 showed	 that	 Sema3A	 signaling	 can	 also	 modulate	 lymphatic	 vessel	maturation,	 as	 Sem3A	 is	 expressed	 by	 lymphatic	 endothelial	 cells	 and	 promotes	perivascular	cell	migration	though	neuropilin-1.	In	vivo	blockade	of	Sema3A	binding	on	neurpilin-1	 resulted	 in	 the	 formation	 of	 aberrant	 lymphatic	 vessels	 with	 impaired	lymphatic	flow	(14).	Thus,	it	will	be	interesting	to	study	if	Sema3A	can	modulate	pericyte	biology	and	investigate	if	the	gene	expression	profile	of	pericyte	is	changing	at	increasing	doses	of	PDGF-BB	and	Sema3A.		
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As	 a	 future	 prospective,	 PDGF-BB	balanced	 co-delivery	 can	 be	 exploited	 to	 accelerate	vascular	 stabilization	 providing	 a	 safe	 and	 efficient	 strategy	 to	 achieve	 short-term	therapeutic	angiogenesis	for	example	using	viral	vector	delivery.	Importantly,	the	ratio	between	 Sema3A	 and	 VEGF	 is	 crucial,	 in	 fact	 Sema3A	 overexpression	 at	 more	 than	physiological	 levels	 through	adeno-associated	viral	delivery	 (AVV)	has	been	 shown	 to	inhibit	VEGF-mediated	angiogenesis	(15).	Therefore,	Sema3A	intrinsic	up-regulation	by	PDGF-BB	might	allow	to	better	control	the	effects	of	Sema3A	only	leading	to	prominent	formation	of	normal	and	stable	vascular	structures.		In	conclusion,	here	we	demonstrated	that	PDGF-BB	not	only	promotes	pericyte	recruitment	during	vessel	maturation	and	stabilization,	but	it	can	also	dose-dependently	favor	vascular	stabilization	independently	of	pericytes	through	Sema3A	expression	and	the	NEM/TGF-b1	axis.	These	results	confirm	that	PDGF-BB	co-delivery	has	the	potential	to	 overcome	 the	 limitations	 of	 VEGF	 gene	 delivery	 (dose	 and	 duration),	 providing	 a	rational	strategy	to	improve	the	clinical	outcome	of	patients	with	limb	ischemia.		
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